Sagar Lonial, MD, FACP

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (176 ratings)

Role

Hematology Oncology
Specialty

Myeloma and Plasma Cell Disorders
Research Program

Discovery and Developmental Therapeutics
Practicing Since

2000

Call 404-778-0519

Background

Sagar Lonial, MD, FACP, is internationally recognized as a leading authority in multiple myeloma treatment and research. As a medical oncologist at the Winship Cancer Institute, Dr. Lonial treats patients with multiple myeloma and is a lead member of the bone marrow transplantation team and clinical trials team. He is board certified in hematology and medical oncology.

Dr. Lonial is involved in numerous professional organizations including American Society of Clinical Oncology, American Society of Hematology, and American Society for Blood and Marrow Transplantation. He serves Vice Chair of the Finance Committee of the International Myeloma Society, and serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group. He also serves as President and Chair of the Society of Hematologic Oncology. Additionally, he is on the Scientific Advisory Board for the International Myeloma Foundation.

Titles & Roles

Chief Medical Officer

Winship Cancer Institute of Emory University
Anne and Bernard Gray Family Chair in Cancer

Emory University School of Medicine
Professor and Chair, Department of Hematology and Medical Oncology

Emory University School of Medicine

Education & Training

Education

Fellowship, Hematology & Oncology, 2000
Emory University School of Medicine
Residency, Internal Medicine, 1997
Baylor College of Medicine
Residency, Internal Medicine, 1996
Baylor College of Medicine
Internship, Internal Medicine, 1994
Baylor College of Medicine
Medical Education, MD, 1993
University of Louisville School of Medicine

Board Certifications

Medical Oncology
American Board of Internal Medicine, 2000
Hematology
American Board of Internal Medicine, 2000

Professional Memberships

American College of Physicians
American Society of Bone Marrow Transplant
American Society of Clinical Oncology
American Society of Hematology

Research

Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in the previous 3 years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen, and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post transplant immune recovery.

Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the MMRF, the Lymphoma Research Foundation, and The Leukemia & Lymphoma Society.

View Current Clinical Trials


A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Phase I Conditions Multiple Myeloma, Myeloma, Myeloma Multiple Location Emory University Hospital Midtown, Winship Cancer Institute
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Phase III Conditions Multiple Myeloma Location Winship Cancer Institute
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma Phase II Conditions Multiple Myeloma Location Winship Cancer Institute
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma Phase I/II Conditions Multiple Myeloma, Lymphoma, Non-Hodgkin's Location Winship Cancer Institute
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma Phase I/II Conditions Multiple Myeloma Location Winship Cancer Institute
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma Phase I/II Conditions Hematological Malignancies Location Winship Cancer Institute

Publications

Dr. Lonial has authored or coauthored more than 400 peer-reviewed publications. He serves on the editorial board of the Journal of Clinical Oncology, Leukemia, is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and is the hematologic malignancies section editor for the journal Cancer. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others.

Title/Journal	Authors	Publication Date
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the USA. The Lancet. Haematology	MK Khan, TH Nasti, JY Qian, TJ Kleber, JM Switchenko, JL Kaufman, AJ Nooka, MV Dhodapkar, ZS Buchwald, D Obiekwe, S Lonial, R Ahmed	07/01/2024
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma. Cell reports. Medicine	M Amatangelo, E Flynt, N Stong, P Ray, O Van Oekelen, M Wang, M Ortiz, P Maciag, T Peluso, S Parekh, NWCJ van de Donk, S Lonial, A Thakurta	06/18/2024
Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cells. Nucleic acids research	M Cinar, L Martinez-Medina, PK Puvvula, A Arakelyan, BN Vardarajan, N Anthony, GP Nagaraju, D Park, L Feng, F Sheff, M Mosunjac, D Saxe, S Flygare, OB Alese, JL Kaufman, S Lonial, JM Sarmiento, IS Lossos, PM Vertino, JA Lopez, B El-Rayes, L Bernal-Mizrachi	05/23/2024
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma. bioRxiv : the preprint server for biology	WC Pilcher, L Yao, E Gonzalez-Kozlova, Y Pita-Juarez, D Karagkouni, CR Acharya, ME Michaud, M Hamilton, S Nanda, Y Song, K Sato, JT Wang, S Satpathy, Y Ma, J Schulman, D D'Souza, RG Jayasinghe, G Cheloni, M Bakhtiari, N Pabustan, K Nie, JA Foltz, I Saldarriaga, R Alaaeldin, E Lepisto, R Chen, MA Fiala, BE Thomas, A Cook, JV Dos Santos, IL Chiang, I Figueiredo, J Fortier, M Slade, ST Oh, MP Rettig, E Anderson, Y Li, S Dasari, MA Strausbauch, VA Simon, AH Rahman, Z Chen, A Lagana, JF DiPersio, J Rosenblatt, S Kim-Schulze, MV Dhodapkar, S Lonial, S Kumar, SS Bhasin, T Kourelis, R Vij, D Avigan, HJ Cho, G Mulligan, L Ding, S Gnjatic, IS Vlachos, M Bhasin	05/17/2024
Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive CAR-T Cell Therapies with Multiple Myeloma. bioRxiv : the preprint server for biology	D Ghoshal, I Petersen, R Ringquist, L Kramer, E Bhatia, T Hu, A Richard, R Park, J Corbin, S Agarwal, A Thomas, S Ramirez, J Tharayil, E Downey, F Ketchum, A Ochal, N Sonthi, S Lonial, JN Kochenderfer, R Tran, M Zhu, WA Lam, AF Coskun, K Roy	04/12/2024
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA Vaccination. Research square	F Lee, D Nguyen, I Hentenaar, A Morrison-Porter, D Solano, N Haddad, C Castrillon, P Lamothe, J Andrews, D Roberts, S Lonial, I Sanz	03/13/2024
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA Vaccination. medRxiv : the preprint server for health sciences	DC Nguyen, IT Hentenaar, A Morrison-Porter, D Solano, NS Haddad, C Castrillon, PA Lamothe, J Andrews, D Roberts, S Lonial, I Sanz, FE Lee	03/05/2024
Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival culture. Scientific reports	DC Nguyen, C Saney, IT Hentenaar, M Cabrera-Mora, V Capric, MC Woodruff, J Andrews, S Lonial, I Sanz, FE Lee	02/13/2024
Shrinking the divide: improving myeloma CART access. Blood advances	AK Nooka, MA Hartley-Brown, KC Anderson, S Lonial	01/09/2024
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma. Blood cancer discovery	P Neri, BG Barwick, D Jung, JC Patton, R Maity, I Tagoug, CK Stein, R Tilmont, N Leblay, S Ahn, H Lee, SJ Welsh, DL Riggs, N Stong, E Flynt, A Thakurta, JJ Keats, S Lonial, PL Bergsagel, LH Boise, NJ Bahlis	01/08/2024
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma. Blood cancer discovery	SJ Welsh, BG Barwick, EW Meermeier, DL Riggs, CX Shi, YX Zhu, ME Sharik, MT Du, LD Abrego Rocha, VM Garbitt, CK Stein, JL Petit, N Meurice, Y Tafoya Alvarado, R Fonseca, KT Todd, S Brown, ZJ Hammond, NH Cuc, C Wittenberg, C Herzog, AV Roschke, YN Demchenko, WD Chen, P Li, W Liao, WJ Leonard, S Lonial, NJ Bahlis, P Neri, LH Boise, M Chesi, PL Bergsagel	01/08/2024
Glücksklee, the Quad, and High-Risk Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, JL Kaufman, S Lonial	01/01/2024
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience. Blood cancer journal	SA Scott, EM Marin, KT Maples, NS Joseph, CC Hofmeister, VA Gupta, MV Dhodapkar, JL Kaufman, S Lonial, AK Nooka	12/20/2023
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer	AK Nooka, AD Cohen, HC Lee, A Badros, A Suvannasankha, N Callander, AO Abdallah, S Trudel, A Chari, EN Libby, M Chaudhry, M Hultcrantz, KM Kortüm, R Popat, D Sborov, S Hakim, E Lewis, B Gorsh, B Bhushan, A McKeown, I Gupta, J Opalinska, PG Richardson, S Lonial	12/01/2023
Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	S Lonial, AD Bowser, A Chari, C Costello, A Krishnan, SZ Usmani	11/01/2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial. EJHaem	PG Richardson, T Facon, CP Venner, NJ Bahlis, F Offner, D White, L Karlin, L Benboubker, E Voog, SS Yoon, K Suzuki, H Shibayama, X Zhang, M Villarreal, P Twumasi-Ankrah, R Labotka, RM Rifkin, S Lonial, SK Kumar, SV Rajkumar, P Moreau	11/01/2023
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica	PG Richardson, BG Durie, L Rosiñol, MV Mateos, A Dispenzieri, P Moreau, S Kumar, N Raje, N Munshi, JP Laubach, P O'Gorman, E O'Donnell, P Voorhees, T Facon, J Bladé, S Lonial, A Perrot, KC Anderson	11/01/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. Research square	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	09/21/2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. The New England journal of medicine	PG Richardson, S Trudel, R Popat, MV Mateos, AJ Vangsted, K Ramasamy, J Martinez-Lopez, H Quach, RZ Orlowski, M Arnao, S Lonial, C Karanes, C Pawlyn, K Kim, A Oriol, JG Berdeja, P Rodríguez Otero, I Casas-Avilés, A Spirli, J Poon, S Li, J Gong, L Wong, M Lamba, DW Pierce, M Amatangelo, T Peluso, P Maciag, J Katz, M Pourdehnad, NJ Bahlis	09/14/2023
Majority of human circulating plasmablasts stop blasting: A probable misnomer. bioRxiv : the preprint server for biology	DC Nguyen, C Saney, IT Hentenaar, M Cabrera-Mora, MC Woodruff, J Andrews, S Lonial, I Sanz, FE Lee	09/13/2023
Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel. Blood cancer discovery	B Paiva, I Manrique, J Rytlewski, T Campbell, CC Kazanecki, N Martin, LD Anderson, JG Berdeja, S Lonial, NS Raje, Y Lin, P Moreau, JF San-Miguel, NC Munshi, SM Kaiser	09/01/2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction. JCO oncology practice	LF Sun, KT Maples, KH Hall, Y Liu, Y Cao, NS Joseph, CC Hofmeister, JL Kaufman, M Dhodapkar, AK Nooka, S Lonial, RD Harvey	09/01/2023
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma. Journal of the advanced practitioner in oncology	R Popat, S Lonial, PM Voorhees, SD Esposti, B Gorsh, I Gupta, J Opalinska, S Sapra, T Piontek, Z He, D Kleinman, D Schaumberg, A Regnault, J Meunier, L Eliason	09/01/2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunity. bioRxiv : the preprint server for biology	A Moreno, K Manning, MI Azeem, AK Nooka, M Ellis, RJ Manalo, JM Switchenko, B Wali, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar, MS Suthar	08/22/2023
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood cancer journal	N Raje, K Anderson, H Einsele, Y Efebera, F Gay, SP Hammond, AM Lesokhin, S Lonial, H Ludwig, P Moreau, K Patel, K Ramasamy, MV Mateos	08/01/2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy. The Journal of clinical investigation	MH Robinson, NY Villa, DL Jaye, AK Nooka, A Duffy, SS McCachren, J Manalo, JM Switchenko, S Barnes, S Potdar, MI Azeem, AA Horvat, VC Parihar, J Gong, Y Liang, GH Smith, VA Gupta, LH Boise, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, KM Dhodapkar, MV Dhodapkar	08/01/2023
Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. Cell reports	M Duan, DC Nguyen, CJ Joyner, CL Saney, CM Tipton, J Andrews, S Lonial, C Kim, I Hentenaar, A Kosters, E Ghosn, A Jackson, S Knechtle, S Maruthamuthu, S Chandran, T Martin, R Rajalingam, F Vincenti, C Breeden, I Sanz, G Gibson, FE Lee	07/25/2023
Novel approaches to the treatment of multiple myeloma. Clinical advances in hematology & oncology : H&O	KT Maples, SA Scott, S Lonial	05/01/2023
Disparities in multiple myeloma among African Americans. Journal of the National Medical Association	M Bhutani, S Lonial, J Mikhael	05/01/2023
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections. Blood cancer discovery	MI Azeem, AK Nooka, U Shanmugasundaram, N Cheedarla, S Potdar, RJ Manalo, A Moreno, JM Switchenko, S Cheedarla, DB Doxie, R Radzievski, ML Ellis, KE Manning, B Wali, RM Valanparambil, KT Maples, E Baymon, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, JD Roback, A Sette, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar, KM Dhodapkar	03/01/2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience. Blood cancer journal	KT Maples, KH Hall, NS Joseph, CC Hofmeister, V Gupta, MV Dhodapkar, JL Kaufman, AK Nooka, S Lonial	02/20/2023
Human Bone Marrow Plasma Cell Atlas: Maturation and Survival Pathways Unraveled by Single Cell Analyses. bioRxiv : the preprint server for biology	M Duan, DC Nguyen, CJ Joyner, CL Saney, CM Tipton, J Andrews, S Lonial, C Kim, I Hentenaar, A Kosters, E Ghosn, A Jackson, S Knechtle, S Maruthamuthu, S Chandran, T Martin, R Rajalingam, F Vincenti, C Breeden, I Sanz, G Gibson, F Eun-Hyung Lee	01/20/2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma. Blood cancer journal	WJ Chng, S Lonial, GJ Morgan, S Iida, P Moreau, SK Kumar, P Twumasi-Ankrah, M Villarreal, AB Dash, A Vorog, X Zhang, K Suryanarayan, R Labotka, MA Dimopoulos, SV Rajkumar	01/12/2023
Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. CA: a cancer journal for clinicians	RH Parikh, S Lonial	01/01/2023
Optimizing the benefits of BCMA-targeted CAR T-cell therapy in multiple myeloma. Clinical advances in hematology & oncology : H&O	S Lonial	01/01/2023
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial. The Lancet. Haematology	S Lonial, R Popat, C Hulin, S Jagannath, A Oriol, PG Richardson, T Facon, K Weisel, JT Larsen, MC Minnema, AO Abdallah, AZ Badros, S Knop, EA Stadtmauer, Y Cheng, M Amatangelo, M Chen, TV Nguyen, A Amin, T Peluso, NWCJ van de Donk	11/01/2022
EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit. Clinical lymphoma, myeloma & leukemia	AK Nooka, S Lonial	10/01/2022
When an embarrassment of riches isn't enough. Nature reviews. Clinical oncology	K Patel, S Lonial	10/01/2022
Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma. Science advances	A Sharma, R Nair, A Achreja, A Mittal, P Gupta, K Balakrishnan, CL Edgar, O Animasahun, B Dwivedi, BG Barwick, VA Gupta, SM Matulis, M Bhasin, S Lonial, AK Nooka, AP Wiita, LH Boise, D Nagrath, M Shanmugam	09/30/2022
Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	AK Nooka, U Shanmugasundaram, N Cheedarla, H Verkerke, VV Edara, R Valanparambil, JL Kaufman, CC Hofmeister, NS Joseph, S Lonial, M Azeem, J Manalo, JM Switchenko, A Chang, SL Linderman, JD Roback, KM Dhodapkar, R Ahmed, MS Suthar, AS Neish, MV Dhodapkar	09/10/2022
Smoldering multiple myeloma current treatment algorithms. Blood cancer journal	SV Rajkumar, S Kumar, S Lonial, MV Mateos	09/05/2022
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. Haematologica	R Nair, V Subramaniam, BG Barwick, VA Gupta, SM Matulis, S Lonial, LH Boise, AK Nooka, K Muthumalaiappan, M Shanmugam	09/01/2022
Venetoclax ex vivo functional profiling predicts improved progression-free survival. Blood cancer journal	VA Gupta, SM Matulis, BG Barwick, RD Bog, CW Shebelut, M Shanmugam, P Neri, NJ Bahlis, MV Dhodapkar, LT Heffner, CC Hofmeister, NS Joseph, S Lonial, JL Kaufman, DL Jaye, AK Nooka, LH Boise	08/04/2022
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. The New England journal of medicine	PG Richardson, SJ Jacobus, EA Weller, H Hassoun, S Lonial, NS Raje, E Medvedova, PL McCarthy, EN Libby, PM Voorhees, RZ Orlowski, LD Anderson, JA Zonder, CP Milner, C Gasparetto, ME Agha, AM Khan, DD Hurd, K Gowin, RT Kamble, S Jagannath, N Nathwani, M Alsina, RF Cornell, H Hashmi, EL Campagnaro, AC Andreescu, T Gentile, M Liedtke, KN Godby, AD Cohen, TH Openshaw, MC Pasquini, SA Giralt, JL Kaufman, AJ Yee, E Scott, P Torka, A Foley, M Fulciniti, K Hebert, MK Samur, K Masone, ME Maglio, AA Zeytoonjian, O Nadeem, RL Schlossman, JP Laubach, C Paba-Prada, IM Ghobrial, A Perrot, P Moreau, H Avet-Loiseau, M Attal, KC Anderson, NC Munshi	07/14/2022
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood cancer discovery	FE Davies, C Pawlyn, SZ Usmani, JF San-Miguel, H Einsele, EM Boyle, J Corre, D Auclair, HJ Cho, S Lonial, P Sonneveld, AK Stewart, PL Bergsagel, MF Kaiser, K Weisel, JJ Keats, JR Mikhael, KE Morgan, IM Ghobrial, RZ Orlowski, CO Landgren, F Gay, J Caers, WJ Chng, A Chari, BA Walker, SK Kumar, LJ Costa, KC Anderson, GJ Morgan	07/06/2022
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	MA Dimopoulos, P Richardson, S Lonial	07/01/2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. The Lancet. Haematology	MA Dimopoulos, PG Richardson, NJ Bahlis, S Grosicki, M Cavo, M Beksaç, W Legieć, AM Liberati, H Goldschmidt, A Belch, H Magen, A Larocca, JP Laubach, MT Petrucci, D Reece, D White, MV Mateos, I Špička, M Lazaroiu, J Berdeja, JL Kaufman, YM Jou, A Ganetsky, M Popa McKiver, S Lonial, K Weisel	06/01/2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. Transplantation and cellular therapy	B Dhakal, N Shah, A Kansagra, A Kumar, S Lonial, A Garfall, A Cowan, BS Poudyal, C Costello, F Gay, G Cook, H Quach, H Einsele, J Schriber, J Hou, L Costa, M Aljurf, M Chaudhry, M Beksac, M Prince, M Mohty, M Janakiram, N Callander, N Biran, P Malhotra, PR Otero, P Moreau, R Abonour, R Iftikhar, R Silberman, S Mailankody, T Gregory, Y Lin, P Carpenter, M Hamadani, S Usmani, S Kumar	06/01/2022
Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. Cell	X Mo, Q Niu, AA Ivanov, YH Tsang, C Tang, C Shu, Q Li, K Qian, A Wahafu, SP Doyle, D Cicka, X Yang, D Fan, MA Reyna, LAD Cooper, CS Moreno, W Zhou, TK Owonikoko, S Lonial, FR Khuri, Y Du, SS Ramalingam, GB Mills, H Fu	05/26/2022
Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting. Life science alliance	CJ Joyner, AM Ley, DC Nguyen, M Ali, A Corrado, C Tipton, CD Scharer, T Mi, MC Woodruff, J Hom, JM Boss, M Duan, G Gibson, D Roberts, J Andrews, S Lonial, I Sanz, FE Lee	03/01/2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Pharmacotherapy	A Sivakumar, EB Bryson, KH Hall, KT Maples, S Goyal, NS Joseph, CC Hofmeister, JL Kaufman, S Lonial, AK Nooka, RD Harvey	03/01/2022
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. The Lancet. Haematology	NS Raje, E Anaissie, SK Kumar, S Lonial, T Martin, MA Gertz, A Krishnan, P Hari, H Ludwig, E O'Donnell, A Yee, JL Kaufman, AD Cohen, L Garderet, AF Wechalekar, E Terpos, N Khatry, R Niesvizky, Q Yi, DE Joshua, T Saikia, N Leung, M Engelhardt, M Mothy, A Branagan, A Chari, AJ Reiman, B Lipe, J Richter, SV Rajkumar, JS Miguel, KC Anderson, EA Stadtmauer, RH Prabhala, PL McCarthy, NC Munshi	02/01/2022
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice. The Lancet. Haematology	S Lonial, SV Rajkumar, MV Mateos	02/01/2022
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. Transplantation and cellular therapy	NS Joseph, VA Gupta, S Wyman, M Graiser, JL Kaufman, D Almaula, J Andrews, C Hofmeister, M Dhodapkar, LT Heffner, S Lonial, AK Nooka	02/01/2022
"I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma. Cancer	AK Nooka, NS Joseph, S Lonial	11/15/2021
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer	S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, N Callander, D Sborov, A Suvannasankha, K Weisel, PM Voorhees, L Womersley, J Baron, T Piontek, E Lewis, J Opalinska, I Gupta, AD Cohen	11/15/2021
Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. Blood cancer discovery	A Kaushal, AK Nooka, AR Carr, KE Pendleton, BG Barwick, J Manalo, SS McCachren, VA Gupta, NS Joseph, CC Hofmeister, JL Kaufman, LT Heffner, SM Ansell, LH Boise, S Lonial, KM Dhodapkar, MV Dhodapkar	11/01/2021
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. The Lancet. Haematology	KR Kelly, S Ailawadhi, DS Siegel, LT Heffner, G Somlo, S Jagannath, TM Zimmerman, NC Munshi, S Madan, A Chanan-Khan, S Lonial, S Chandwani, A Minasyan, M Ruehle, F Barmaki-Rad, A Abdolzade-Bavil, F Rharbaoui, E Herrmann-Keiner, T Haeder, A Wartenberg-Demand, KC Anderson	11/01/2021
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical cancer research : an official journal of the American Association for Cancer Research	KC Anderson, D Auclair, SJ Adam, A Agarwal, M Anderson, H Avet-Loiseau, M Bustoros, J Chapman, DE Connors, A Dash, A Di Bacco, L Du, T Facon, J Flores-Montero, F Gay, IM Ghobrial, NJ Gormley, I Gupta, H Higley, J Hillengass, B Kanapuru, D Kazandjian, GJ Kelloff, IR Kirsch, B Kremer, O Landgren, E Lightbody, OC Lomas, S Lonial, MV Mateos, R Montes de Oca, L Mukundan, NC Munshi, EK O'Donnell, A Orfao, B Paiva, R Patel, TJ Pugh, K Ramasamy, J Ray, M Roshal, JA Ross, CC Sigman, KL Thoren, S Trudel, G Ulaner, N Valente, BM Weiss, E Zamagni, SK Kumar	10/01/2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	A Jakubowiak, SZ Usmani, A Krishnan, S Lonial, RL Comenzo, J Wang, C de Boer, W Deraedt, BM Weiss, JM Schecter, A Chari	10/01/2021
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. Cancers	J Ackley, MA Ochoa, D Ghoshal, K Roy, S Lonial, LH Boise	09/24/2021
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Molecular cell	D Chen, S Xia, R Zhang, Y Li, CA Famulare, H Fan, R Wu, M Wang, AC Zhu, SE Elf, R Su, L Dong, M Arellano, WG Blum, H Mao, S Lonial, W Stock, O Odenike, M Le Beau, TJ Boggon, C He, J Chen, X Gao, RL Levine, J Chen	09/16/2021
Selinexor for the treatment of patients with previously treated multiple myeloma. Expert review of hematology	CC Mo, S Jagannath, A Chari, AK Nooka, S Lonial, D Siegel, N Biran, C Gasparetto, NJ Bahlis, P Richardson	08/01/2021
What The Princess Bride Teaches Us About Outcomes in Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A D'Souza, S Lonial	08/01/2021
Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood	T Facon, CP Venner, NJ Bahlis, F Offner, DJ White, L Karlin, L Benboubker, S Rigaudeau, P Rodon, E Voog, SS Yoon, K Suzuki, H Shibayama, X Zhang, P Twumasi-Ankrah, G Yung, RM Rifkin, P Moreau, S Lonial, SK Kumar, PG Richardson, SV Rajkumar	07/01/2021
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood	VA Gupta, BG Barwick, SM Matulis, R Shirasaki, DL Jaye, JJ Keats, B Oberlton, NS Joseph, CC Hofmeister, LT Heffner, MV Dhodapkar, AK Nooka, S Lonial, CS Mitsiades, JL Kaufman, LH Boise	07/01/2021
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	BG Barwick, VA Gupta, SM Matulis, JC Patton, DR Powell, Y Gu, DL Jaye, KN Conneely, YC Lin, CC Hofmeister, AK Nooka, JJ Keats, S Lonial, PM Vertino, LH Boise	06/01/2021
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood cancer journal	S Lonial, AK Nooka, P Thulasi, AZ Badros, BH Jeng, NS Callander, HA Potter, D Sborov, BE Zaugg, R Popat, S Degli Esposti, J Byrne, J Opalinska, J Baron, T Piontek, I Gupta, R Dana, AV Farooq, K Colby, A Jakubowiak	05/26/2021
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	H Avet-Loiseau, J San-Miguel, T Casneuf, S Iida, S Lonial, SZ Usmani, A Spencer, P Moreau, T Plesner, K Weisel, J Ukropec, C Chiu, S Trivedi, H Amin, M Krevvata, P Ramaswami, X Qin, M Qi, S Sun, M Qi, R Kobos, NJ Bahlis	04/01/2021
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. American journal of hematology	KT Maples, AK Nooka, V Gupta, NS Joseph, LT Heffner, C Hofmeister, M Dhodapkar, SM Matulis, S Lonial, LH Boise, JL Kaufman	03/01/2021
Antibody treatment in multiple myeloma. Clinical advances in hematology & oncology : H&O	KT Maples, C Johnson, S Lonial	03/01/2021
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell-Inflamed Phenotype. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer	TK Owonikoko, B Dwivedi, Z Chen, C Zhang, B Barwick, V Ernani, G Zhang, M Gilbert-Ross, J Carlisle, FR Khuri, WJ Curran, AA Ivanov, H Fu, S Lonial, SS Ramalingam, SY Sun, EK Waller, GL Sica	03/01/2021
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. The Lancet. Oncology	P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, H Ludwig, J Mikhael, E Terpos, F Schjesvold, T Martin, K Yong, BGM Durie, T Facon, A Jurczyszyn, S Sidana, N Raje, N van de Donk, S Lonial, M Cavo, SY Kristinsson, S Lentzsch, R Hajek, KC Anderson, C João, H Einsele, P Sonneveld, M Engelhardt, R Fonseca, A Vangsted, K Weisel, R Baz, V Hungria, JG Berdeja, F Leal da Costa, A Maiolino, A Waage, DH Vesole, EM Ocio, H Quach, C Driessen, J Bladé, X Leleu, E Riva, PL Bergsagel, J Hou, WJ Chng, UH Mellqvist, D Dytfeld, JL Harousseau, H Goldschmidt, J Laubach, NC Munshi, F Gay, M Beksac, LJ Costa, M Kaiser, P Hari, M Boccadoro, SZ Usmani, S Zweegman, S Holstein, O Sezer, S Harrison, H Nahi, G Cook, MV Mateos, SV Rajkumar, MA Dimopoulos, PG Richardson	03/01/2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. The New England journal of medicine	NC Munshi, LD Anderson, N Shah, D Madduri, J Berdeja, S Lonial, N Raje, Y Lin, D Siegel, A Oriol, P Moreau, I Yakoub-Agha, M Delforge, M Cavo, H Einsele, H Goldschmidt, K Weisel, A Rambaldi, D Reece, F Petrocca, M Massaro, JN Connarn, S Kaiser, P Patel, L Huang, TB Campbell, K Hege, J San-Miguel	02/25/2021
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. EJHaem	PG Richardson, S Jagannath, A Chari, DT Vogl, MA Dimopoulos, P Moreau, D Dingli, LJ Wei, J Richter, N Biran, D Siegel, W Reichmann, L Li, S Tang, JR Saint-Martin, A Joshi, M Kauffman, J Shah, S Shacham, S Lonial	02/01/2021
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. American journal of hematology	R Cornell, P Hari, S Tang, N Biran, N Callander, A Chari, S Chhabra, MA Fiala, Z Gahvari, U Gandhi, K Godby, R Gupta, S Jagannath, M Jagosky, Y Kang, A Kansagra, M Kauffman, S Kodali, SK Kumar, A Lakshman, M Liedtke, S Lonial, X Ma, E Malek, J Mansour, EF McGehee, A Neppalli, B Paul, P Richardson, EC Scott, S Shacham, J Shah, DS Siegel, E Umyarova, SZ Usmani, W Varnado, R Vij, L Costa	01/01/2021
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	YC Cohen, A Oriol, KL Wu, N Lavi, P Vlummens, C Jackson, W Garvin, R Carson, W Crist, J Fu, H Feng, H Xie, J Schecter, J San-Miguel, S Lonial	01/01/2021
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Clinical pharmacology : advances and applications	NS Joseph, YT Tai, KC Anderson, S Lonial	01/01/2021
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. The Lancet. Oncology	JP Laubach, F Schjesvold, M Mariz, MA Dimopoulos, E Lech-Maranda, I Spicka, VTM Hungria, T Shelekhova, A Abdo, L Jacobasch, C Polprasert, R Hájek, Á Illés, T Wróbel, A Sureda, M Beksac, IZ Gonçalves, J Bladé, SV Rajkumar, A Chari, S Lonial, A Spencer, P Maison-Blanche, P Moreau, JF San-Miguel, PG Richardson	01/01/2021
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. Blood cancer journal	Y Gu, BG Barwick, M Shanmugam, CC Hofmeister, J Kaufman, A Nooka, V Gupta, M Dhodapkar, LH Boise, S Lonial	12/14/2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	JL Kaufman, R Mina, JJ Shah, JP Laubach, AK Nooka, C Lewis, C Gleason, C Sharp, RD Harvey, LT Heffner, P Richardson, S Lonial, RZ Orlowski	12/01/2020
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study. Journal for immunotherapy of cancer	S Pakkala, K Higgins, Z Chen, G Sica, C Steuer, C Zhang, G Zhang, S Wang, MS Hossain, B Nazha, T Beardslee, FR Khuri, W Curran, S Lonial, EK Waller, S Ramalingam, TK Owonikoko	12/01/2020
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	MA Dimopoulos, I Špička, H Quach, A Oriol, R Hájek, M Garg, M Beksac, S Bringhen, E Katodritou, WJ Chng, X Leleu, S Iida, MV Mateos, G Morgan, A Vorog, R Labotka, B Wang, A Palumbo, S Lonial	12/01/2020
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy	AV Farooq, S Degli Esposti, R Popat, P Thulasi, S Lonial, AK Nooka, A Jakubowiak, D Sborov, BE Zaugg, AZ Badros, BH Jeng, NS Callander, J Opalinska, J Baron, T Piontek, J Byrne, I Gupta, K Colby	12/01/2020
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and therapy	AV Farooq, S Degli Esposti, R Popat, P Thulasi, S Lonial, AK Nooka, A Jakubowiak, D Sborov, BE Zaugg, AZ Badros, BH Jeng, NS Callander, J Opalinska, J Baron, T Piontek, J Byrne, I Gupta, K Colby	12/01/2020
We need CD38 STAT-JAK. Blood	BG Barwick, S Lonial	11/12/2020
Practical approach to the management of smoldering myeloma. Current opinion in oncology	NS Joseph, S Lonial	11/01/2020
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood cancer journal	PG Richardson, HC Lee, AO Abdallah, AD Cohen, P Kapoor, PM Voorhees, A Hoos, K Wang, J Baron, T Piontek, J Byrne, S Richmond, RC Jewell, J Opalinska, I Gupta, S Lonial	10/23/2020
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. British journal of cancer	RD Harvey, BC Carthon, C Lewis, MS Hossain, C Zhang, Z Chen, WB Harris, OB Alese, W Shaib, MA Bilen, DH Lawson, C Wu, CE Steuer, BF El-Rayes, FR Khuri, S Lonial, EK Waller, SS Ramalingam, TK Owonikoko	10/01/2020
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO oncology practice	Y Yu, N Brown Wade, AE Hwang, AK Nooka, MA Fiala, A Mohrbacher, ES Peters, K Pawlish, C Bock, DJ Van Den Berg, KA Rand, D Stram, DV Conti, D Auclair, GA Colditz, J Mehta, CA Haiman, H Terebelo, N Janakiraman, S Singhal, B Chiu, R Vij, L Bernal-Mizrachi, JA Zonder, CA Huff, S Lonial, RZ Orlowski, W Cozen, S Ailawadhi	10/01/2020
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. The Lancet. Oncology	SK Kumar, SJ Jacobus, AD Cohen, M Weiss, N Callander, AK Singh, TL Parker, A Menter, X Yang, B Parsons, P Kumar, P Kapoor, A Rosenberg, JA Zonder, E Faber, S Lonial, KC Anderson, PG Richardson, RZ Orlowski, LI Wagner, SV Rajkumar	10/01/2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood cancer journal	MA Dimopoulos, S Lonial, D White, P Moreau, K Weisel, J San-Miguel, O Shpilberg, S Grosicki, I Špička, A Walter-Croneck, H Magen, MV Mateos, A Belch, D Reece, M Beksac, A Spencer, H Oakervee, RZ Orlowski, M Taniwaki, C Röllig, H Einsele, M Matsumoto, KL Wu, KC Anderson, YM Jou, A Ganetsky, AK Singhal, PG Richardson	09/04/2020
Message from the Chairmen. Clinical lymphoma, myeloma & leukemia	S Lonial, H Kantarjian, EJ Freireich	09/01/2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia	M Gavriatopoulou, A Chari, C Chen, N Bahlis, DT Vogl, A Jakubowiak, D Dingli, RF Cornell, CC Hofmeister, D Siegel, JG Berdeja, D Reece, D White, S Lentzsch, C Gasparetto, CA Huff, S Jagannath, R Baz, AK Nooka, J Richter, R Abonour, TL Parker, AJ Yee, P Moreau, S Lonial, S Tuchman, KC Weisel, M Mohty, S Choquet, TJ Unger, K Li, Y Chai, L Li, J Shah, S Shacham, MG Kauffman, MA Dimopoulos	09/01/2020
Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations and Outcomes. JCO oncology practice	P Cinar, J Cox, A Kamal, K Bickel, M Krzyzanowska, J Armitage, AK Ganti, J Ward, S Wong, S Lonial, L Bosserman	08/01/2020
Smoldering Myeloma and the Art of War. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, MV Dhodapkar, SV Rajkumar	07/20/2020
DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling. Clinical cancer research : an official journal of the American Association for Cancer Research	J Li, C Pan, AC Boese, J Kang, AD Umano, KR Magliocca, W Yang, Y Zhang, S Lonial, L Jin, S Kang	07/15/2020
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	NS Joseph, JL Kaufman, MV Dhodapkar, CC Hofmeister, DK Almaula, LT Heffner, VA Gupta, LH Boise, S Lonial, AK Nooka	06/10/2020
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research	TK Owonikoko, RD Harvey, B Carthon, Z Chen, C Lewis, H Collins, C Zhang, DH Lawson, OB Alese, MA Bilen, GL Sica, CE Steuer, WL Shaib, C Wu, WB Harris, M Akce, RR Kudchagkar, BF El-Rayes, S Lonial, SS Ramalingam, FR Khuri	06/01/2020
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. The Lancet. Haematology	SZ Usmani, H Nahi, T Plesner, BM Weiss, NJ Bahlis, A Belch, PM Voorhees, JP Laubach, NWCJ van de Donk, T Ahmadi, CM Uhlar, J Wang, H Feng, M Qi, PG Richardson, S Lonial	06/01/2020
Reply to N. Biran et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, MV Dhodapkar, SV Rajkumar	04/20/2020
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. Blood cancer journal	R Mina, NS Joseph, F Gay, E Kastritis, MT Petrucci, JL Kaufman, V Montefusco, M Gavriatopoulou, F Patriarca, P Omedé, LH Boise, M Roussou, N Giuliani, S Oliva, M Offidani, A Belotti, DL Jaye, L De Paoli, E Terpos, S Lonial, M Boccadoro, AK Nooka, MA Dimopoulos	04/14/2020
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, S Jacobus, R Fonseca, M Weiss, S Kumar, RZ Orlowski, JL Kaufman, AM Yacoub, FK Buadi, T O'Brien, JV Matous, DM Anderson, RV Emmons, A Mahindra, LI Wagner, MV Dhodapkar, SV Rajkumar	04/10/2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Advances in therapy	XS Xu, P Moreau, SZ Usmani, S Lonial, A Jakubowiak, A Oriol, A Krishnan, J Bladé, M Luo, YN Sun, H Zhou, I Nnane, W Deraedt, M Qi, J Ukropec, PL Clemens	04/01/2020
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nature communications	R Bajpai, A Sharma, A Achreja, CL Edgar, C Wei, AA Siddiqa, VA Gupta, SM Matulis, SK McBrayer, A Mittal, M Rupji, BG Barwick, S Lonial, AK Nooka, LH Boise, D Nagrath, M Shanmugam	03/06/2020
The Role of Early Intervention in High-Risk Smoldering Myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	NS Joseph, MV Dhodapkar, S Lonial	03/01/2020
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. The Lancet. Oncology	S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, N Callander, N Lendvai, D Sborov, A Suvannasankha, K Weisel, L Karlin, E Libby, B Arnulf, T Facon, C Hulin, KM Kortüm, P Rodríguez-Otero, SZ Usmani, P Hari, R Baz, H Quach, P Moreau, PM Voorhees, I Gupta, A Hoos, E Zhi, J Baron, T Piontek, E Lewis, RC Jewell, EJ Dettman, R Popat, SD Esposti, J Opalinska, P Richardson, AD Cohen	02/01/2020
A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood advances	Z Du, N Weinhold, GC Song, KA Rand, DJ Van Den Berg, AE Hwang, X Sheng, V Hom, S Ailawadhi, AK Nooka, S Singhal, K Pawlish, ES Peters, C Bock, A Mohrbacher, A Stram, SI Berndt, WJ Blot, G Casey, VL Stevens, R Kittles, PJ Goodman, WR Diver, A Hennis, B Nemesure, EA Klein, BA Rybicki, JL Stanford, JS Witte, L Signorello, EM John, L Bernstein, AM Stroup, OW Stephens, M Zangari, F Van Rhee, A Olshan, W Zheng, JJ Hu, R Ziegler, SJ Nyante, SA Ingles, MF Press, JD Carpten, SJ Chanock, J Mehta, GA Colditz, J Wolf, TG Martin, M Tomasson, MA Fiala, H Terebelo, N Janakiraman, L Kolonel, KC Anderson, L Le Marchand, D Auclair, BC Chiu, E Ziv, D Stram, R Vij, L Bernal-Mizrachi, GJ Morgan, JA Zonder, CA Huff, S Lonial, RZ Orlowski, DV Conti, CA Haiman, W Cozen	01/14/2020
γ-6-Phosphogluconolactone, a Byproduct of the Oxidative Pentose Phosphate Pathway, Contributes to AMPK Activation through Inhibition of PP2A. Molecular cell	X Gao, L Zhao, S Liu, Y Li, S Xia, D Chen, M Wang, S Wu, Q Dai, H Vu, L Zacharias, R DeBerardinis, E Lim, C Metallo, TJ Boggon, S Lonial, R Lin, H Mao, Y Pan, C Shan, J Chen	12/19/2019
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood cancer journal	TM Schmidt, BG Barwick, N Joseph, LT Heffner, CC Hofmeister, L Bernal, MV Dhodapkar, VA Gupta, DL Jaye, J Wu, S Goyal, Z Chen, LH Boise, S Lonial, AK Nooka, JL Kaufman	11/25/2019
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. The Journal of clinical investigation	C Pan, J Chun, D Li, AC Boese, J Li, J Kang, A Umano, Y Jiang, L Song, KR Magliocca, ZG Chen, NF Saba, DM Shin, TK Owonikoko, S Lonial, L Jin, S Kang	10/01/2019
Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Cancer	AK Nooka, NS Joseph, JL Kaufman, LT Heffner, VA Gupta, C Gleason, LH Boise, S Lonial	09/01/2019
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. Clinical lymphoma, myeloma & leukemia	D Madduri, MV Dhodapkar, S Lonial, S Jagannath, HJ Cho	09/01/2019
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. The Lancet. Haematology	SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, R LeBlanc, N Takezako, RD McCroskey, ABM Lim, K Suzuki, H Kosugi, G Grigoriadis, I Avivi, T Facon, S Jagannath, S Lonial, RU Ghori, MZH Farooqui, P Marinello, J San-Miguel	09/01/2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. The Lancet. Haematology	MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, H Goldschmidt, A Larocca, A Chanan-Khan, D Sherbenou, I Avivi, N Benyamini, S Iida, M Matsumoto, K Suzuki, V Ribrag, SZ Usmani, S Jagannath, EM Ocio, P Rodriguez-Otero, J San Miguel, U Kher, M Farooqui, J Liao, P Marinello, S Lonial	09/01/2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. The New England journal of medicine	A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, P Moreau, D Dingli, C Cole, S Lonial, M Dimopoulos, AK Stewart, J Richter, R Vij, S Tuchman, MS Raab, KC Weisel, M Delforge, RF Cornell, D Kaminetzky, JE Hoffman, LJ Costa, TL Parker, M Levy, M Schreder, N Meuleman, L Frenzel, M Mohty, S Choquet, G Schiller, RL Comenzo, M Engelhardt, T Illmer, P Vlummens, C Doyen, T Facon, L Karlin, A Perrot, K Podar, MG Kauffman, S Shacham, L Li, S Tang, C Picklesimer, JR Saint-Martin, M Crochiere, H Chang, S Parekh, Y Landesman, J Shah, PG Richardson, S Jagannath	08/22/2019
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood	A Chari, J Martinez-Lopez, MV Mateos, J Bladé, L Benboubker, A Oriol, B Arnulf, P Rodriguez-Otero, L Pineiro, A Jakubowiak, C de Boer, J Wang, PL Clemens, J Ukropec, J Schecter, S Lonial, P Moreau	08/01/2019
Is there still a role for stem cell transplantation in multiple myeloma? Cancer	R Mina, S Lonial	08/01/2019
Daratumumab in multiple myeloma. Cancer	AK Nooka, JL Kaufman, CC Hofmeister, NS Joseph, TL Heffner, VA Gupta, HC Sullivan, AS Neish, MV Dhodapkar, S Lonial	07/15/2019
Registering a CD38 antibody upfront for multiple myeloma. Lancet (London, England)	CC Hofmeister, A Nooka, JL Kaufman, S Lonial	07/06/2019
Reply to African American patients may or may not have poorer response rates after monoclonal antibody treatment: Overreliance on P values in underpowered studies. Cancer	RD Harvey, C Zhang, S Lonial, JL Kaufman, Z Chen	07/01/2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia	SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, AK Stewart, P Hari, V Roy, R Vescio, JL Kaufman, D Berg, E Liao, SV Rajkumar, PG Richardson	07/01/2019
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer discovery	D Chen, S Xia, M Wang, R Lin, Y Li, H Mao, M Aguiar, CA Famulare, AH Shih, CW Brennan, X Gao, Y Pan, S Liu, J Fan, L Jin, L Song, A Zhou, J Mukherjee, RO Pieper, A Mishra, J Peng, M Arellano, WG Blum, S Lonial, TJ Boggon, RL Levine, J Chen	06/01/2019
Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical lymphoma, myeloma & leukemia	I Ghobrial, CH Cruz, A Garfall, N Shah, N Munshi, J Kaufman, LH Boise, G Morgan, VA Adalsteinsson, S Manier, R Pillai, F Malavasi, S Lonial	06/01/2019
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	S Jagannath, LT Heffner, S Ailawadhi, NC Munshi, TM Zimmerman, J Rosenblatt, S Lonial, A Chanan-Khan, M Ruehle, F Rharbaoui, T Haeder, A Wartenberg-Demand, KC Anderson	06/01/2019
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet. Oncology	J Hillengass, S Usmani, SV Rajkumar, BGM Durie, MV Mateos, S Lonial, C Joao, KC Anderson, R García-Sanz, E Riva, J Du, N van de Donk, JG Berdeja, E Terpos, E Zamagni, RA Kyle, J San Miguel, H Goldschmidt, S Giralt, S Kumar, N Raje, H Ludwig, E Ocio, R Schots, H Einsele, F Schjesvold, WM Chen, N Abildgaard, BC Lipe, D Dytfeld, BM Wirk, M Drake, M Cavo, JJ Lahuerta, S Lentzsch	06/01/2019
Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. The Journal of clinical investigation	C Pan, L Jin, X Wang, Y Li, J Chun, AC Boese, D Li, HB Kang, G Zhang, L Zhou, GZ Chen, NF Saba, DM Shin, KR Magliocca, TK Owonikoko, H Mao, S Lonial, S Kang	05/13/2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. Leukemia	SM Matulis, VA Gupta, P Neri, NJ Bahlis, P Maciag, JD Leverson, LT Heffner, S Lonial, AK Nooka, JL Kaufman, LH Boise	05/01/2019
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI insight	JK Bailur, SS McCachren, DB Doxie, M Shrestha, K Pendleton, AK Nooka, N Neparidze, TL Parker, N Bar, JL Kaufman, CC Hofmeister, LH Boise, S Lonial, ML Kemp, KM Dhodapkar, MV Dhodapkar	04/23/2019
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. Nature communications	BG Barwick, P Neri, NJ Bahlis, AK Nooka, MV Dhodapkar, DL Jaye, CC Hofmeister, JL Kaufman, VA Gupta, D Auclair, JJ Keats, S Lonial, PM Vertino, LH Boise	04/23/2019
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Cytometry. Part A : the journal of the International Society for Analytical Cytology	HC Adams, F Stevenaert, J Krejcik, K Van der Borght, T Smets, J Bald, Y Abraham, H Ceulemans, C Chiu, G Vanhoof, SZ Usmani, T Plesner, S Lonial, I Nijhof, HM Lokhorst, T Mutis, NWCJ van de Donk, AK Sasser, T Casneuf	03/01/2019
Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. British journal of haematology	NWCJ van de Donk, T Casneuf, A Di Cara, PW Parren, S Zweegman, B van Kessel, HM Lokhorst, SZ Usmani, S Lonial, PG Richardson, C Chiu, T Mutis, IS Nijhof, AK Sasser	02/01/2019
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer	R Mina, NS Joseph, JL Kaufman, VA Gupta, LT Heffner, CC Hofmeister, LH Boise, MV Dhodapkar, C Gleason, AK Nooka, S Lonial	02/01/2019
Safety and survival outcomes for bloodless transplantation in patients with myeloma. Cancer	NS Joseph, JL Kaufman, LH Boise, K Valla, DK Almaula, CO Obidike, AA Langston, EK Waller, HJ Khoury, CR Flowers, M Graiser, LT Heffner, S Lonial, AK Nooka	01/15/2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood cancer journal	JL Kaufman, R Mina, AJ Jakubowiak, TL Zimmerman, JJ Wolf, C Lewis, C Gleason, C Sharp, T Martin, LT Heffner, AK Nooka, RD Harvey, S Lonial	01/04/2019
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma. Cancer journal (Sudbury, Mass.)	AK Nooka, S Lonial	01/01/2019
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia	BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, A Rosenthal, H Wang, P Qu, A Hoering, M Samur, F Towfic, M Ortiz, E Flynt, Z Yu, Z Yang, D Rozelle, J Obenauer, M Trotter, D Auclair, J Keats, N Bolli, M Fulciniti, R Szalat, P Moreau, B Durie, AK Stewart, H Goldschmidt, MS Raab, H Einsele, P Sonneveld, J San Miguel, S Lonial, GH Jackson, KC Anderson, H Avet-Loiseau, N Munshi, A Thakurta, G Morgan	01/01/2019
Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models. PloS one	TK Owonikoko, G Zhang, SB Lallani, Z Chen, DE Martinson, FR Khuri, S Lonial, A Marcus, SY Sun	01/01/2019
Ixazomib for the treatment of multiple myeloma. Expert opinion on pharmacotherapy	PG Richardson, S Zweegman, EK O'Donnell, JP Laubach, N Raje, P Voorhees, RH Ferrari, T Skacel, SK Kumar, S Lonial	12/01/2018
Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma. Future oncology (London, England)	S Chehab, EH Panjic, C Gleason, S Lonial, AK Nooka	12/01/2018
Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. Cancer	S Chehab, C Zhang, EH Panjic, Z Chen, JL Kaufman, S Lonial, A Nooka, RD Harvey	11/15/2018
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer	A Chari, S Lonial, TM Mark, AY Krishnan, KE Stockerl-Goldstein, SZ Usmani, A Londhe, D Etheredge, S Fleming, B Liu, J Ukropec, TS Lin, S Jagannath, AK Nooka	11/15/2018
Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy. Cancer letters	G Qian, W Yao, S Zhang, R Bajpai, WD Hall, M Shanmugam, S Lonial, SY Sun	10/28/2018
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer	MA Dimopoulos, S Lonial, KA Betts, C Chen, ML Zichlin, A Brun, JE Signorovitch, D Makenbaeva, S Mekan, O Sy, K Weisel, PG Richardson	10/15/2018
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica	JF San-Miguel, MA Echeveste Gutierrez, I Špicka, MV Mateos, K Song, MD Craig, J Bladé, R Hájek, C Chen, A Di Bacco, J Estevam, N Gupta, C Byrne, V Lu, H van de Velde, S Lonial	09/01/2018
Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. Journal of oncology practice	A Chang, TH Nasti, MK Khan, S Parashar, JL Kaufman, LH Boise, S Lonial, R Ahmed, AK Nooka	09/01/2018
Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study. Blood cancer journal	J Mikhael, J Manola, AC Dueck, S Hayman, K Oettel, AS Kanate, S Lonial, SV Rajkumar	08/29/2018
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer cell	L Jin, J Chun, C Pan, D Li, R Lin, GN Alesi, X Wang, HB Kang, L Song, D Wang, G Zhang, J Fan, TJ Boggon, L Zhou, J Kowalski, CK Qu, CE Steuer, GZ Chen, NF Saba, LH Boise, TK Owonikoko, FR Khuri, KR Magliocca, DM Shin, S Lonial, S Kang	08/13/2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood	BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, A Rosenthal, H Wang, P Qu, A Hoering, M Samur, F Towfic, M Ortiz, E Flynt, Z Yu, Z Yang, D Rozelle, J Obenauer, M Trotter, D Auclair, J Keats, N Bolli, M Fulciniti, R Szalat, P Moreau, B Durie, AK Stewart, H Goldschmidt, MS Raab, H Einsele, P Sonneveld, J San Miguel, S Lonial, GH Jackson, KC Anderson, H Avet-Loiseau, N Munshi, A Thakurta, GJ Morgan	08/09/2018
Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab. Journal of oncology practice	AK Nooka, C Gleason, MO Sargeant, M Walker, M Watson, EH Panjic, S Lonial	07/01/2018
Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia	A Krishnan, P Kapoor, JM Palmer, NC Tsai, S Kumar, S Lonial, M Htut, C Karanes, N Nathwani, M Rosenzweig, F Sahebi, G Somlo, L Duarte, JF Sanchez, D Auclair, SJ Forman, JG Berdeja	07/01/2018
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial. British journal of haematology	PG Richardson, RL Schlossman, AN Roy, A Panneerselvam, S Acharyya, M Sopala, S Lonial	06/01/2018
Current developments in immunotherapy in the treatment of multiple myeloma. Cancer	M Köhler, C Greil, M Hudecek, S Lonial, N Raje, R Wäsch, M Engelhardt	05/15/2018
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. Clinical pharmacokinetics	X Yan, PL Clemens, T Puchalski, S Lonial, H Lokhorst, PM Voorhees, S Usmani, PG Richardson, T Plesner, K Liu, RZ Orlowski, N Losic, R Jansson, T Ahmadi, K Lantz, JJP Ruixo, H Zhou, XS Xu	04/01/2018
The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. Molecular cell	R Lin, S Xia, C Shan, D Chen, Y Liu, X Gao, M Wang, HB Kang, Y Pan, S Liu, YR Chung, O Abdel-Wahab, T Merghoub, M Rossi, RR Kudchadkar, DH Lawson, FR Khuri, S Lonial, J Chen	03/15/2018
14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia	Y Gu, K Xu, C Torre, M Samur, BG Barwick, M Rupji, J Arora, P Neri, J Kaufman, A Nooka, L Bernal-Mizrachi, P Vertino, SY Sun, J Chen, N Munshi, H Fu, J Kowalski, LH Boise, S Lonial	03/01/2018
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma. Cancer	JJ Shah, JL Kaufman, JA Zonder, AD Cohen, WI Bensinger, BW Hilder, SA Rush, DH Walker, BJ Tunquist, KS Litwiler, M Ptaszynski, RZ Orlowski, S Lonial	12/01/2017
CD86 regulates myeloma cell survival. Blood advances	CM Gavile, BG Barwick, S Newman, P Neri, AK Nooka, S Lonial, KP Lee, LH Boise	11/28/2017
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood advances	T Casneuf, XS Xu, HC Adams, AE Axel, C Chiu, I Khan, T Ahmadi, X Yan, S Lonial, T Plesner, HM Lokhorst, NWCJ van de Donk, PL Clemens, AK Sasser	10/24/2017
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. British journal of haematology	JF San-Miguel, VTM Hungria, SS Yoon, M Beksac, MA Dimopoulos, A Elghandour, WW Jedrzejczak, A Guenther, T Na Nakorn, N Siritanaratkul, RL Schlossman, J Hou, P Moreau, S Lonial, JH Lee, H Einsele, H Salwender, M Sopala, S Redhu, S Paul, C Corrado, PG Richardson	10/01/2017
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent. Expert review of hematology	P Richardson, A Roy, S Acharyya, A Panneerselvam, E Mendelson, A Günther, S Lonial, H Einsele	10/01/2017
TG02 inhibits proteasome inhibitor-induced HSF1 serine 326 phosphorylation and heat shock response in multiple myeloma. Blood advances	SP Shah, AK Nooka, S Lonial, LH Boise	09/26/2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. British journal of haematology	MA Dimopoulos, S Lonial, D White, P Moreau, A Palumbo, J San-Miguel, O Shpilberg, K Anderson, S Grosicki, I Spicka, A Walter-Croneck, H Magen, MV Mateos, A Belch, D Reece, M Beksac, E Bleickardt, V Poulart, J Sheng, O Sy, J Katz, A Singhal, P Richardson	09/01/2017
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clinical lymphoma, myeloma & leukemia	EH van Beers, MH van Vliet, R Kuiper, L de Best, KC Anderson, A Chari, S Jagannath, A Jakubowiak, SK Kumar, JB Levy, D Auclair, S Lonial, D Reece, P Richardson, DS Siegel, AK Stewart, S Trudel, R Vij, TM Zimmerman, R Fonseca	09/01/2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood	A Chari, A Suvannasankha, JW Fay, B Arnulf, JL Kaufman, JJ Ifthikharuddin, BM Weiss, A Krishnan, S Lentzsch, R Comenzo, J Wang, K Nottage, C Chiu, NZ Khokhar, T Ahmadi, S Lonial	08/24/2017
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. British journal of haematology	JP Laubach, JJ Moslehi, SA Francis, JF San Miguel, P Sonneveld, RZ Orlowski, P Moreau, L Rosiñol, EA Faber, P Voorhees, MV Mateos, L Marquez, H Feng, A Desai, H van de Velde, J Elliott, H Shi, E Dow, N Jobanputra, DL Esseltine, L Niculescu, KC Anderson, S Lonial, PG Richardson	08/01/2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. British journal of haematology	S Kumar, P Moreau, P Hari, MV Mateos, H Ludwig, C Shustik, T Masszi, A Spencer, R Hájek, K Romeril, I Avivi, AM Liberati, MC Minnema, H Einsele, S Lonial, D Berg, J Lin, N Gupta, DL Esseltine, PG Richardson	08/01/2017
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment. Clinical pharmacokinetics	PL Clemens, X Yan, HM Lokhorst, S Lonial, N Losic, I Khan, R Jansson, T Ahmadi, K Lantz, H Zhou, T Puchalski, XS Xu	08/01/2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	DT Vogl, N Raje, S Jagannath, P Richardson, P Hari, R Orlowski, JG Supko, D Tamang, M Yang, SS Jones, C Wheeler, RJ Markelewicz, S Lonial	07/01/2017
High-risk Multiple Myeloma: Definition and Management. Clinical lymphoma, myeloma & leukemia	NS Joseph, S Gentili, JL Kaufman, S Lonial, AK Nooka	07/01/2017
HMG-CoA synthase 1 is a synthetic lethal partner of BRAF^V600E in human cancers. The Journal of biological chemistry	L Zhao, J Fan, S Xia, Y Pan, S Liu, G Qian, Z Qian, HB Kang, JL Arbiser, BP Pollack, RR Kudchadkar, DH Lawson, M Rossi, O Abdel-Wahab, T Merghoub, HJ Khoury, FR Khuri, LH Boise, S Lonial, F Chen, J Chen, R Lin	06/16/2017
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood	HC Sullivan, C Gerner-Smidt, AK Nooka, CM Arthur, L Thompson, A Mener, SR Patel, M Yee, RM Fasano, CD Josephson, RM Kaufman, JD Roback, S Lonial, SR Stowell	06/01/2017
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma. Clinical pharmacology and therapeutics	XS Xu, X Yan, T Puchalski, S Lonial, HM Lokhorst, PM Voorhees, T Plesner, K Liu, I Khan, R Jansson, T Ahmadi, JP Ruixo, H Zhou, PL Clemens	06/01/2017
Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study. Infection control and hospital epidemiology	NN Shah, W McClellan, CR Flowers, S Lonial, H Khoury, EK Waller, A Langston, AK Nooka	06/01/2017
Academic, Foundation, and Industry Collaboration in Finding New Therapies. The New England journal of medicine	BW Ramsey, GT Nepom, S Lonial	05/04/2017
Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood	VA Gupta, SM Matulis, JE Conage-Pough, AK Nooka, JL Kaufman, S Lonial, LH Boise	04/06/2017
Role of ¹⁸F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. The Lancet. Oncology	M Cavo, E Terpos, C Nanni, P Moreau, S Lentzsch, S Zweegman, J Hillengass, M Engelhardt, SZ Usmani, DH Vesole, J San-Miguel, SK Kumar, PG Richardson, JR Mikhael, FL da Costa, MA Dimopoulos, C Zingaretti, N Abildgaard, H Goldschmidt, RZ Orlowski, WJ Chng, H Einsele, S Lonial, B Barlogie, KC Anderson, SV Rajkumar, BGM Durie, E Zamagni	04/01/2017
MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. Nucleic acids research	D Wang, H Hashimoto, X Zhang, BG Barwick, S Lonial, LH Boise, PM Vertino, X Cheng	03/17/2017
Deacetylase inhibitors: an advance in myeloma therapy? Expert review of hematology	JP Laubach, JF San-Miguel, V Hungria, J Hou, P Moreau, S Lonial, JH Lee, H Einsele, M Alsina, PG Richardson	03/01/2017
Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma. Pharmacological research	PG Richardson, P Moreau, JP Laubach, ME Maglio, S Lonial, J San-Miguel	03/01/2017
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell metabolism	S Xia, R Lin, L Jin, L Zhao, HB Kang, Y Pan, S Liu, G Qian, Z Qian, E Konstantakou, B Zhang, JT Dong, YR Chung, O Abdel-Wahab, T Merghoub, L Zhou, RR Kudchadkar, DH Lawson, HJ Khoury, FR Khuri, LH Boise, S Lonial, BH Lee, BP Pollack, JL Arbiser, J Fan, QY Lei, J Chen	02/07/2017
Safety of proteasome inhibitors for treatment of multiple myeloma. Expert opinion on drug safety	D Schlafer, KS Shah, EH Panjic, S Lonial	02/01/2017
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin. Oncogene	S Elf, R Lin, S Xia, Y Pan, C Shan, S Wu, S Lonial, M Gaddh, ML Arellano, HJ Khoury, FR Khuri, BH Lee, TJ Boggon, J Fan, J Chen	01/12/2017
How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	CC Hofmeister, S Lonial	12/20/2016
New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	P Neri, NJ Bahlis, S Lonial	12/15/2016
A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology	KA Rand, C Song, E Dean, DJ Serie, K Curtin, X Sheng, D Hu, CA Huff, L Bernal-Mizrachi, MH Tomasson, S Ailawadhi, S Singhal, K Pawlish, ES Peters, CH Bock, A Stram, DJ Van Den Berg, CK Edlund, DV Conti, T Zimmerman, AE Hwang, S Huntsman, J Graff, A Nooka, Y Kong, SL Pregja, SI Berndt, WJ Blot, J Carpten, G Casey, L Chu, WR Diver, VL Stevens, MR Lieber, PJ Goodman, AJ Hennis, AW Hsing, J Mehta, RA Kittles, S Kolb, EA Klein, C Leske, AB Murphy, B Nemesure, C Neslund-Dudas, SS Strom, R Vij, BA Rybicki, JL Stanford, LB Signorello, JS Witte, CB Ambrosone, P Bhatti, EM John, L Bernstein, W Zheng, AF Olshan, JJ Hu, RG Ziegler, SJ Nyante, EV Bandera, BM Birmann, SA Ingles, MF Press, D Atanackovic, MJ Glenn, LA Cannon-Albright, B Jones, G Tricot, TG Martin, SK Kumar, JL Wolf, SL Deming Halverson, N Rothman, AR Brooks-Wilson, SV Rajkumar, LN Kolonel, SJ Chanock, SL Slager, RK Severson, N Janakiraman, HR Terebelo, EE Brown, AJ De Roos, AF Mohrbacher, GA Colditz, GG Giles, JJ Spinelli, BC Chiu, NC Munshi, KC Anderson, J Levy, JA Zonder, RZ Orlowski, S Lonial, NJ Camp, CM Vachon, E Ziv, DO Stram, DJ Hazelett, CA Haiman, W Cozen	12/01/2016
Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. Molecular cell	J Fan, R Lin, S Xia, D Chen, SE Elf, S Liu, Y Pan, H Xu, Z Qian, M Wang, C Shan, L Zhou, QY Lei, Y Li, H Mao, BH Lee, J Sudderth, RJ DeBerardinis, G Zhang, T Owonikoko, M Gaddh, ML Arellano, HJ Khoury, FR Khuri, S Kang, PW Doetsch, S Lonial, TJ Boggon, WJ Curran, J Chen	12/01/2016
Integration of Novel Agents into the Care of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	RZ Orlowski, S Lonial	11/15/2016
HLA polymorphism and risk of multiple myeloma. Leukemia	M Beksac, L Gragert, S Fingerson, M Maiers, MJ Zhang, M Albrecht, X Zhong, W Cozen, A Dispenzieri, S Lonial, P Hari	11/01/2016
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. The Lancet. Haematology	JF San-Miguel, VT Hungria, SS Yoon, M Beksac, MA Dimopoulos, A Elghandour, WW Jedrzejczak, A Günther, TN Nakorn, N Siritanaratkul, RL Schlossman, J Hou, P Moreau, S Lonial, JH Lee, H Einsele, M Sopala, BR Bengoudifa, F Binlich, PG Richardson	11/01/2016
Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation. Cancer	AK Nooka, M Behera, S Lonial, MD Dixon, SS Ramalingam, RD Pentz	10/15/2016
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert opinion on biological therapy	S Lonial, J Kaufman, D Reece, MV Mateos, J Laubach, P Richardson	10/01/2016
Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget	SP Shah, AK Nooka, DL Jaye, NJ Bahlis, S Lonial, LH Boise	09/13/2016
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia? Clinical lymphoma, myeloma & leukemia	Z DeFilipp, AA Langston, Z Chen, C Zhang, ML Arellano, F El Rassi, CR Flowers, VK Kota, Z Al-Kadhimi, R Veldman, AP Jillella, S Lonial, EK Waller, HJ Khoury	08/01/2016
Is Maintenance Therapy for Everyone? Clinical lymphoma, myeloma & leukemia	AK Nooka, S Lonial	08/01/2016
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet. Oncology	S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, N Munshi, S Lonial, J Bladé, MV Mateos, M Dimopoulos, E Kastritis, M Boccadoro, R Orlowski, H Goldschmidt, A Spencer, J Hou, WJ Chng, SZ Usmani, E Zamagni, K Shimizu, S Jagannath, HE Johnsen, E Terpos, A Reiman, RA Kyle, P Sonneveld, PG Richardson, P McCarthy, H Ludwig, W Chen, M Cavo, JL Harousseau, S Lentzsch, J Hillengass, A Palumbo, A Orfao, SV Rajkumar, JS Miguel, H Avet-Loiseau	08/01/2016
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene	R Bajpai, SM Matulis, C Wei, AK Nooka, HE Von Hollen, S Lonial, LH Boise, M Shanmugam	07/28/2016
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood	SZ Usmani, BM Weiss, T Plesner, NJ Bahlis, A Belch, S Lonial, HM Lokhorst, PM Voorhees, PG Richardson, A Chari, AK Sasser, A Axel, H Feng, CM Uhlar, J Wang, I Khan, T Ahmadi, H Nahi	07/07/2016
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer biology & therapy	KG Ponder, SM Matulis, S Hitosugi, VA Gupta, C Sharp, F Burrows, AK Nooka, JL Kaufman, S Lonial, LH Boise	07/02/2016
Death by a thousand cuts: the slow demise of chemotherapy. Cancer	AK Nooka, S Lonial	07/01/2016
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood	P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, KC Anderson, WJ Chng, P Moreau, M Attal, RA Kyle, J Caers, J Hillengass, J San Miguel, NW van de Donk, H Einsele, J Bladé, BG Durie, H Goldschmidt, MV Mateos, A Palumbo, R Orlowski	06/16/2016
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. American journal of hematology	A Jurczyszyn, N Grzasko, A Gozzetti, J Czepiel, A Cerase, V Hungria, E Crusoe, AL Silva Dias, R Vij, MA Fiala, J Caers, L Rasche, AK Nooka, S Lonial, DH Vesole, S Philip, S Gangatharan, A Druzd-Sitek, J Walewski, A Corso, F Cocito, MC Vekemans, E Atilla, M Beksac, X Leleu, J Davila, A Badros, E Aneja, N Abildgaard, E Kastritis, D Fantl, N Schutz, T Pika, A Butrym, M Olszewska-Szopa, L Usnarska-Zubkiewicz, SZ Usmani, H Nahi, CS Chim, C Shustik, K Madry, S Lentzsch, A Swiderska, G Helbig, R Guzicka-Kazimierczak, N Lendvai, A Waage, KT Andersen, H Murakami, S Zweegman, JJ Castillo	06/01/2016
BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth. Oncotarget	J Deng, D Park, M Wang, A Nooka, Q Deng, S Matulis, J Kaufman, S Lonial, LH Boise, J Galipeau, X Deng	05/10/2016
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia	SM Matulis, VA Gupta, AK Nooka, HV Hollen, JL Kaufman, S Lonial, LH Boise	05/01/2016
Novel Combination Treatments in Multiple Myeloma. Oncology (Williston Park, N.Y.)	AK Nooka, S Lonial	05/01/2016
Gene integrated set profile analysis: a context-based approach for inferring biological endpoints. Nucleic acids research	J Kowalski, B Dwivedi, S Newman, JM Switchenko, R Pauly, DA Gutman, J Arora, K Gandhi, K Ainslie, G Doho, Z Qin, CS Moreno, MR Rossi, PM Vertino, S Lonial, L Bernal-Mizrachi, LH Boise	04/20/2016
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet (London, England)	S Lonial, BM Weiss, SZ Usmani, S Singhal, A Chari, NJ Bahlis, A Belch, A Krishnan, RA Vescio, MV Mateos, A Mazumder, RZ Orlowski, HJ Sutherland, J Bladé, EC Scott, A Oriol, J Berdeja, M Gharibo, DA Stevens, R LeBlanc, M Sebag, N Callander, A Jakubowiak, D White, J de la Rubia, PG Richardson, S Lisby, H Feng, CM Uhlar, I Khan, T Ahmadi, PM Voorhees	04/09/2016
Myeloma Is Not a Single Disease. Journal of oncology practice	S Lonial, AK Nooka	04/01/2016
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood	PG Richardson, VT Hungria, SS Yoon, M Beksac, MA Dimopoulos, A Elghandour, WW Jedrzejczak, A Guenther, TN Nakorn, N Siritanaratkul, RL Schlossman, J Hou, P Moreau, S Lonial, JH Lee, H Einsele, M Sopala, BR Bengoudifa, C Corrado, F Binlich, JF San-Miguel	02/11/2016
Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting. Clinical advances in hematology & oncology : H&O	S Lonial	02/01/2016
Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenström macroglobulinemia. Oncogene	BT Gaudette, B Dwivedi, KS Chitta, S Poulain, D Powell, P Vertino, X Leleu, S Lonial, AA Chanan-Khan, J Kowalski, LH Boise	01/28/2016
New Targets and New Agents in High-Risk Multiple Myeloma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting	AK Nooka, S Lonial	01/01/2016
Emerging treatments in Castleman disease - a critical appraisal of siltuximab. Biologics : targets & therapy	JL Koff, S Lonial	01/01/2016
Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38. Cancer journal (Sudbury, Mass.)	S Lonial	01/01/2016
Treatment of MM: Upcoming Novel Therapies. Cancer treatment and research	S Lonial	01/01/2016
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research	JJ Shah, AJ Jakubowiak, OA O'Connor, RZ Orlowski, RD Harvey, MR Smith, D Lebovic, C Diefenbach, K Kelly, Z Hua, AJ Berger, G Mulligan, HM Faessel, S Tirrell, BJ Dezube, S Lonial	01/01/2016
Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert review of clinical pharmacology	PG Richardson, RD Harvey, JP Laubach, P Moreau, S Lonial, JF San-Miguel	01/01/2016
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	S Giralt, L Garderet, B Durie, G Cook, G Gahrton, B Bruno, P Hari, H Lokhorst, P McCarthy, A Krishnan, P Sonneveld, H Goldschmidt, S Jagannath, B Barlogie, M Mateos, P Gimsing, O Sezer, J Mikhael, J Lu, M Dimopoulos, A Mazumder, A Palumbo, R Abonour, K Anderson, M Attal, J Blade, J Bird, M Cavo, R Comenzo, J de la Rubia, H Einsele, R Garcia-Sanz, J Hillengass, S Holstein, HE Johnsen, D Joshua, G Koehne, S Kumar, R Kyle, X Leleu, S Lonial, H Ludwig, H Nahi, A Nooka, R Orlowski, V Rajkumar, A Reiman, P Richardson, E Riva, J San Miguel, I Turreson, S Usmani, D Vesole, W Bensinger, M Qazilbash, Y Efebera, M Mohty, C Gasparreto, J Gajewski, CF LeMaistre, C Bredeson, P Moreau, M Pasquini, N Kroeger, E Stadtmauer	12/01/2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. The Lancet. Haematology	PG Richardson, S Jagannath, P Moreau, AJ Jakubowiak, MS Raab, T Facon, R Vij, D White, DE Reece, L Benboubker, J Zonder, LC Tsao, KC Anderson, E Bleickardt, AK Singhal, S Lonial	12/01/2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. British journal of haematology	JB Cohen, JM Switchenko, JL Koff, R Sinha, JL Kaufman, HJ Khoury, N Bumpers, A Colbert, A Hutchison-Rzepka, LJ Nastoupil, LT Heffner, AA Langston, MJ Lechowicz, S Lonial, CR Flowers	11/01/2015
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nature cell biology	R Lin, S Elf, C Shan, HB Kang, Q Ji, L Zhou, T Hitosugi, L Zhang, S Zhang, JH Seo, J Xie, M Tucker, TL Gu, J Sudderth, L Jiang, M Mitsche, RJ DeBerardinis, S Wu, Y Li, H Mao, PR Chen, D Wang, GZ Chen, SJ Hurwitz, S Lonial, ML Arellano, HJ Khoury, FR Khuri, BH Lee, Q Lei, DJ Brat, K Ye, TJ Boggon, C He, S Kang, J Fan, J Chen	11/01/2015
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Transfusion	N Jagirdar, RD Harvey, A Nooka, C Flowers, J Kaufman, S Lonial, MJ Lechowicz, A Langston, C Lipscomb, C Gaylor, EK Waller	10/01/2015
How I treat high-risk myeloma. Blood	S Lonial, LH Boise, J Kaufman	09/24/2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, L Rosinol, P Richardson, S Caltagirone, JJ Lahuerta, T Facon, S Bringhen, F Gay, M Attal, R Passera, A Spencer, M Offidani, S Kumar, P Musto, S Lonial, MT Petrucci, RZ Orlowski, E Zamagni, G Morgan, MA Dimopoulos, BG Durie, KC Anderson, P Sonneveld, J San Miguel, M Cavo, SV Rajkumar, P Moreau	09/10/2015
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia	JB Cohen, S Bucur, EF Winton, R Sinha, LT Heffner, N King, S Lonial, AA Langston, EK Waller, A Hutchison-Rzepka, A Colbert, MJ Lechowicz, CR Flowers	09/01/2015
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. The New England journal of medicine	S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, A Walter-Croneck, P Moreau, MV Mateos, H Magen, A Belch, D Reece, M Beksac, A Spencer, H Oakervee, RZ Orlowski, M Taniwaki, C Röllig, H Einsele, KL Wu, A Singhal, J San-Miguel, M Matsumoto, J Katz, E Bleickardt, V Poulart, KC Anderson, P Richardson	08/13/2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Molecular cell	HB Kang, J Fan, R Lin, S Elf, Q Ji, L Zhao, L Jin, JH Seo, C Shan, JL Arbiser, C Cohen, D Brat, HM Miziorko, E Kim, O Abdel-Wahab, T Merghoub, S Fröhling, C Scholl, P Tamayo, DA Barbie, L Zhou, BP Pollack, K Fisher, RR Kudchadkar, DH Lawson, G Sica, M Rossi, S Lonial, HJ Khoury, FR Khuri, BH Lee, TJ Boggon, C He, S Kang, J Chen	08/06/2015
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic proceedings	A Tefferi, H Kantarjian, SV Rajkumar, LH Baker, JL Abkowitz, JW Adamson, RH Advani, J Allison, KH Antman, RC Bast, JM Bennett, EJ Benz, N Berliner, J Bertino, R Bhatia, S Bhatia, D Bhojwani, CD Blanke, CD Bloomfield, L Bosserman, HE Broxmeyer, JC Byrd, F Cabanillas, GP Canellos, BA Chabner, A Chanan-Khan, B Cheson, B Clarkson, SL Cohn, G Colon-Otero, J Cortes, S Coutre, M Cristofanilli, WJ Curran, GQ Daley, DJ DeAngelo, HJ Deeg, LH Einhorn, HP Erba, FJ Esteva, E Estey, IJ Fidler, J Foran, S Forman, E Freireich, C Fuchs, JN George, MA Gertz, S Giralt, H Golomb, P Greenberg, J Gutterman, RI Handin, S Hellman, PM Hoff, R Hoffman, WK Hong, M Horowitz, GN Hortobagyi, C Hudis, JP Issa, BE Johnson, PW Kantoff, K Kaushansky, D Khayat, FR Khuri, TJ Kipps, M Kripke, RA Kyle, RA Larson, TS Lawrence, R Levine, MP Link, SM Lippman, S Lonial, GH Lyman, M Markman, J Mendelsohn, NJ Meropol, Y Messinger, TM Mulvey, S O'Brien, R Perez-Soler, R Pollock, J Prchal, O Press, J Radich, K Rai, SA Rosenberg, JM Rowe, H Rugo, CD Runowicz, BM Sandmaier, A Saven, AI Schafer, C Schiffer, MA Sekeres, RT Silver, LL Siu, DP Steensma, FM Stewart, W Stock, R Stone, R Storb, LC Strong, MS Tallman, M Thompson, NT Ueno, RA Van Etten, JM Vose, PH Wiernik, EP Winer, A Younes, AD Zelenetz, CA LeMaistre	08/01/2015
When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. Molecular cancer research : MCR	SP Shah, S Lonial, LH Boise	08/01/2015
Treatment options for relapsed and refractory multiple myeloma. Blood	AK Nooka, E Kastritis, MA Dimopoulos, S Lonial	05/14/2015
New cancers after autotransplantations for multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	A Mahindra, G Raval, P Mehta, R Brazauskas, MJ Zhang, X Zhong, JM Bird, CO Freytes, GA Hale, R Herzig, LA Holmberg, RT Kamble, S Kumar, HM Lazarus, NS Majhail, DI Marks, JS Moreb, R Olsson, W Saber, BN Savani, GJ Schiller, J Tay, DT Vogl, EK Waller, PH Wiernik, B Wirk, S Lonial, AY Krishnan, A Dispenzieri, NA Brandenburg, RP Gale, PN Hari	04/01/2015
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood	A Palumbo, S Bringhen, MV Mateos, A Larocca, T Facon, SK Kumar, M Offidani, P McCarthy, A Evangelista, S Lonial, S Zweegman, P Musto, E Terpos, A Belch, R Hajek, H Ludwig, AK Stewart, P Moreau, K Anderson, H Einsele, BG Durie, MA Dimopoulos, O Landgren, JF San Miguel, P Richardson, P Sonneveld, SV Rajkumar	03/26/2015
Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. Cancer	MS Barbee, A Nooka, JL Kaufman, S Kim, Z Chen, LT Heffner, S Lonial, RD Harvey	03/15/2015
Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leukemia & lymphoma	LJ Nastoupil, PJ Shenoy, A Ambinder, JL Koff, AK Nooka, EK Waller, A Langston, M Seward, JL Kaufman, L Bernal-Mizrachi, N King, MJ Lechowicz, S Lonial, R Sinha, CR Flowers	02/01/2015
Novel combination approaches for myeloma. Hematology. American Society of Hematology. Education Program	S Lonial, AK Nooka	01/01/2015
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. The Lancet. Oncology	SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, AK Stewart, P Hari, V Roy, R Vescio, JL Kaufman, D Berg, E Liao, A Di Bacco, J Estevam, N Gupta, AM Hui, V Rajkumar, PG Richardson	12/01/2014
Older patients with myeloma derive similar benefit from autologous transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	M Sharma, MJ Zhang, X Zhong, MH Abidi, G Akpek, U Bacher, NS Callander, A Dispenzieri, CO Freytes, HC Fung, RP Gale, C Gasparetto, J Gibson, LA Holmberg, TL Kindwall-Keller, TR Klumpp, AY Krishnan, HJ Landau, HM Lazarus, S Lonial, A Maiolino, DI Marks, P Mehta, JR Mikhael Med, T Nishihori, R Olsson, M Ramanathan, V Roy, BN Savani, HC Schouten, E Scott, J Tay, LB To, DH Vesole, DT Vogl, P Hari	11/01/2014
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet. Oncology	SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, S Kumar, J Hillengass, E Kastritis, P Richardson, O Landgren, B Paiva, A Dispenzieri, B Weiss, X LeLeu, S Zweegman, S Lonial, L Rosinol, E Zamagni, S Jagannath, O Sezer, SY Kristinsson, J Caers, SZ Usmani, JJ Lahuerta, HE Johnsen, M Beksac, M Cavo, H Goldschmidt, E Terpos, RA Kyle, KC Anderson, BG Durie, JF Miguel	11/01/2014
Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. Clinical lymphoma, myeloma & leukemia	N Raje, B Faiman, RD Harvey, SE Kurtin, S Lonial, SK Kumar, AD Cohen, MA Conde, SA Giralt, MS Recine, ER Tombler, E Stadtmauer, S Jagannath, KC Anderson	10/01/2014
Relapsed and refractory multiple myeloma: new therapeutic strategies. Hematology/oncology clinics of North America	S Gentili, S Lonial	10/01/2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. The Lancet. Oncology	JF San-Miguel, VT Hungria, SS Yoon, M Beksac, MA Dimopoulos, A Elghandour, WW Jedrzejczak, A Günther, TN Nakorn, N Siritanaratkul, P Corradini, S Chuncharunee, JJ Lee, RL Schlossman, T Shelekhova, K Yong, D Tan, T Numbenjapon, JD Cavenagh, J Hou, R LeBlanc, H Nahi, L Qiu, H Salwender, S Pulini, P Moreau, K Warzocha, D White, J Bladé, W Chen, J de la Rubia, P Gimsing, S Lonial, JL Kaufman, EM Ocio, L Veskovski, SK Sohn, MC Wang, JH Lee, H Einsele, M Sopala, C Corrado, BR Bengoudifa, F Binlich, PG Richardson	10/01/2014
The Tao of myeloma. Blood	LH Boise, JL Kaufman, NJ Bahlis, S Lonial, KP Lee	09/18/2014
Novel drug combinations for the management of relapsed/refractory multiple myeloma. Clinical lymphoma, myeloma & leukemia	SZ Usmani, S Lonial	09/01/2014
Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Molecular cell	C Shan, S Elf, Q Ji, HB Kang, L Zhou, T Hitosugi, L Jin, R Lin, L Zhang, JH Seo, J Xie, M Tucker, TL Gu, J Sudderth, L Jiang, RJ DeBerardinis, S Wu, Y Li, H Mao, PR Chen, D Wang, GZ Chen, S Lonial, ML Arellano, HJ Khoury, FR Khuri, BH Lee, DJ Brat, K Ye, TJ Boggon, C He, S Kang, J Fan, J Chen	08/21/2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood	PG Richardson, R Baz, M Wang, AJ Jakubowiak, JP Laubach, RD Harvey, M Talpaz, D Berg, G Liu, J Yu, N Gupta, A Di Bacco, AM Hui, S Lonial	08/14/2014
Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	AK Nooka, HR Johnson, JL Kaufman, CR Flowers, A Langston, C Steuer, M Graiser, Z Ali, NN Shah, S Rangaraju, D Nickleach, J Gao, S Lonial, EK Waller	06/01/2014
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. Blood	Y Gu, JL Kaufman, L Bernal, C Torre, SM Matulis, RD Harvey, J Chen, SY Sun, LH Boise, S Lonial	05/22/2014
Down to the bitter end. Blood	S Lonial, C Gleason	05/15/2014
Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series. Clinical lymphoma, myeloma & leukemia	AK Nooka, RD Harvey, A Langston, H Collins, S Lonial, JL Kaufman	04/01/2014
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood	PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, C Chen, S Lonial, A Jakubowiak, N Bahlis, K Song, A Belch, N Raje, C Shustik, S Lentzsch, M Lacy, J Mikhael, J Matous, D Vesole, M Chen, MH Zaki, C Jacques, Z Yu, KC Anderson	03/20/2014
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood	PG Richardson, W Xie, S Jagannath, A Jakubowiak, S Lonial, NS Raje, M Alsina, IM Ghobrial, RL Schlossman, NC Munshi, A Mazumder, DH Vesole, JL Kaufman, K Colson, M McKenney, LE Lunde, J Feather, ME Maglio, D Warren, D Francis, T Hideshima, R Knight, DL Esseltine, CS Mitsiades, E Weller, KC Anderson	03/06/2014
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	A Saad, A Mahindra, MJ Zhang, X Zhong, LJ Costa, A Dispenzieri, WR Drobyski, CO Freytes, RP Gale, CJ Gasparetto, LA Holmberg, RT Kamble, AY Krishnan, RA Kyle, D Marks, T Nishihori, MC Pasquini, M Ramanathan, S Lonial, BN Savani, W Saber, M Sharma, ML Sorror, BM Wirk, PN Hari	03/01/2014
Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. Bone marrow transplantation	CO Freytes, DH Vesole, J LeRademacher, X Zhong, RP Gale, RA Kyle, DE Reece, J Gibson, HC Schouten, PL McCarthy, S Lonial, AY Krishnan, A Dispenzieri, PN Hari	03/01/2014
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia	AK Nooka, JL Kaufman, S Muppidi, A Langston, LT Heffner, C Gleason, D Casbourne, D Saxe, LH Boise, S Lonial	03/01/2014
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia	EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, R Orlowski, S Kumar, S Usmani, D Roodman, R Niesvizky, H Einsele, KC Anderson, MA Dimopoulos, H Avet-Loiseau, UH Mellqvist, I Turesson, G Merlini, R Schots, P McCarthy, L Bergsagel, CS Chim, JJ Lahuerta, J Shah, A Reiman, J Mikhael, S Zweegman, S Lonial, R Comenzo, WJ Chng, P Moreau, P Sonneveld, H Ludwig, BG Durie, JF Miguel	03/01/2014
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. The Lancet. Oncology	A Palumbo, S Bringhen, SK Kumar, G Lupparelli, S Usmani, A Waage, A Larocca, B van der Holt, P Musto, M Offidani, MT Petrucci, A Evangelista, S Zweegman, AK Nooka, A Spencer, MA Dimopoulos, R Hajek, M Cavo, P Richardson, S Lonial, G Ciccone, M Boccadoro, K Anderson, B Barlogie, P Sonneveld, PL McCarthy	03/01/2014
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	A Palumbo, SV Rajkumar, JF San Miguel, A Larocca, R Niesvizky, G Morgan, O Landgren, R Hajek, H Einsele, KC Anderson, MA Dimopoulos, PG Richardson, M Cavo, A Spencer, AK Stewart, K Shimizu, S Lonial, P Sonneveld, BG Durie, P Moreau, RZ Orlowski	02/20/2014
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex. Molecular cell	J Fan, C Shan, HB Kang, S Elf, J Xie, M Tucker, TL Gu, M Aguiar, S Lonning, H Chen, M Mohammadi, LM Britton, BA Garcia, M Alečković, Y Kang, S Kaluz, N Devi, EG Van Meir, T Hitosugi, JH Seo, S Lonial, M Gaddh, M Arellano, HJ Khoury, FR Khuri, TJ Boggon, S Kang, J Chen	02/20/2014
Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors. Bone marrow transplantation	AA Langston, JM Prichard, S Muppidi, A Nooka, MJ Lechowicz, S Lonial, R Sinha, M Graiser, JL Kaufman, HJ Khoury, CR Flowers, EK Waller	02/01/2014
Current strategies for treatment of relapsed/refractory multiple myeloma. Expert review of hematology	JP Laubach, PM Voorhees, H Hassoun, A Jakubowiak, S Lonial, PG Richardson	02/01/2014
Association of response endpoints with survival outcomes in multiple myeloma. Leukemia	S Lonial, KC Anderson	02/01/2014
High-risk myeloma: when to transplant-or not. Seminars in oncology	DM Eicher, S Lonial, F Cavallo, A Palumbo, B Nair, S Waheed, C Hofmeister, HJ Rogers	02/01/2014
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood	G Mulligan, DI Lichter, A Di Bacco, SJ Blakemore, A Berger, E Koenig, H Bernard, W Trepicchio, B Li, R Neuwirth, N Chattopadhyay, JB Bolen, AJ Dorner, H van de Velde, D Ricci, S Jagannath, JR Berenson, PG Richardson, EA Stadtmauer, RZ Orlowski, S Lonial, KC Anderson, P Sonneveld, JF San Miguel, DL Esseltine, M Schu	01/30/2014
Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma. Cancer informatics	R Yang, L Chen, S Newman, K Gandhi, G Doho, CS Moreno, PM Vertino, L Bernal-Mizarchi, S Lonial, LH Boise, M Rossi, J Kowalski, ZS Qin	01/01/2014
Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials. Cancer	AK Nooka, JL Kaufman, M Behera, A Langston, EK Waller, CR Flowers, C Gleason, LH Boise, S Lonial	12/01/2013
Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia	R Sinha, PJ Shenoy, N King, MJ Lechowicz, K Bumpers, D Hutcherson, M Arellano, A Langston, J Kaufman, LT Heffner, EK Waller, A Nooka, CR Flowers, S Lonial	12/01/2013
Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert opinion on biological therapy	S Lonial, J Kaufman, J Laubach, P Richardson	12/01/2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	LJ Costa, MJ Zhang, X Zhong, A Dispenzieri, S Lonial, A Krishnan, C Freytes, D Vesole, RP Gale, K Anderson, B Wirk, BN Savani, EK Waller, H Schouten, H Lazarus, K Meehan, M Sharma, R Kamble, R Vij, S Kumar, T Nishihori, T Kindwall-Keller, W Saber, PN Hari	11/01/2013
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica	D Siegel, T Martin, A Nooka, RD Harvey, R Vij, R Niesvizky, AZ Badros, S Jagannath, L McCulloch, K Rajangam, S Lonial	11/01/2013
"A fortuitous combination of circumstances". Blood	S Lonial	10/17/2013
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood	PG Richardson, RL Schlossman, M Alsina, DM Weber, SE Coutre, C Gasparetto, S Mukhopadhyay, MS Ondovik, M Khan, CS Paley, S Lonial	10/03/2013
The future of drug development and therapy in myeloma. Seminars in oncology	S Lonial, LH Boise	10/01/2013
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. The Lancet. Oncology	M Dimopoulos, DS Siegel, S Lonial, J Qi, R Hajek, T Facon, L Rosinol, C Williams, H Blacklock, H Goldschmidt, V Hungria, A Spencer, A Palumbo, T Graef, JE Eid, J Houp, L Sun, S Vuocolo, KC Anderson	10/01/2013
Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	RD Harvey, JL Kaufman, HR Johnson, A Nooka, L Vaughn, CR Flowers, HJ Khoury, MJ Lechowicz, AA Langston, S Lonial, EK Waller	09/01/2013
Non-secretory myeloma: a clinician's guide. Oncology (Williston Park, N.Y.)	S Lonial, JL Kaufman	09/01/2013
Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. The Annals of pharmacotherapy	MS Barbee, RD Harvey, S Lonial, JL Kaufman, NM Wilson, T McKibbin, DA Hutcherson, M Surati, K Valla, KS Shah	09/01/2013
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clinical lymphoma, myeloma & leukemia	JL Kaufman, C Fabre, S Lonial, PG Richardson	08/01/2013
Rare myelomas: sometimes when you hear hooves, it's a zebra.. Oncology (Williston Park, N.Y.)	S Gentili, S Lonial	08/01/2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clinical cancer research : an official journal of the American Association for Cancer Research	R Kurzrock, PM Voorhees, C Casper, RR Furman, L Fayad, S Lonial, H Borghaei, S Jagannath, L Sokol, SZ Usmani, H van de Velde, X Qin, TA Puchalski, B Hall, M Reddy, M Qi, F van Rhee	07/01/2013
Salvage second hematopoietic cell transplantation in myeloma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	LC Michaelis, A Saad, X Zhong, J Le-Rademacher, CO Freytes, DI Marks, HM Lazarus, JM Bird, L Holmberg, RT Kamble, S Kumar, M Lill, KR Meehan, W Saber, J Schriber, J Tay, DT Vogl, B Wirk, BN Savani, RP Gale, DH Vesole, GJ Schiller, M Abidi, KC Anderson, T Nishihori, ME Kalaycio, JM Vose, JS Moreb, W Drobyski, R Munker, V Roy, A Ghobadi, HK Holland, R Nath, LB To, A Maiolino, AA Kassim, SA Giralt, H Landau, HC Schouten, RT Maziarz, J Mikhael, T Kindwall-Keller, PJ Stiff, J Gibson, S Lonial, A Krishnan, A Dispenzieri, P Hari	05/01/2013
Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	S Lonial, M Akhtari, J Kaufman, C Torre, MJ Lechowicz, C Flowers, R Sinha, HJ Khoury, AA Langston, EK Waller	03/01/2013
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib. Biologics : targets & therapy	A Nooka, C Gleason, D Casbourne, S Lonial	01/01/2013
Induction therapy for newly diagnosed multiple myeloma. Journal of the National Comprehensive Cancer Network : JNCCN	S Lonial, JF Miguel	01/01/2013
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation. Nature communications	T Hitosugi, L Zhou, J Fan, S Elf, L Zhang, J Xie, Y Wang, TL Gu, M Alečković, G LeRoy, Y Kang, HB Kang, JH Seo, C Shan, P Jin, W Gong, S Lonial, ML Arellano, HJ Khoury, GZ Chen, DM Shin, FR Khuri, TJ Boggon, S Kang, C He, J Chen	01/01/2013
A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Transfusion	JL Kaufman, CR Flowers, KD Rados, GB Calandra, JM Vose, LB Hewes, S Lonial, AA Langston, HJ Khoury, MJ Lechowicz, EK Waller	01/01/2013
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer cell	T Hitosugi, L Zhou, S Elf, J Fan, HB Kang, JH Seo, C Shan, Q Dai, L Zhang, J Xie, TL Gu, P Jin, M Alečković, G LeRoy, Y Kang, JA Sudderth, RJ DeBerardinis, CH Luan, GZ Chen, S Muller, DM Shin, TK Owonikoko, S Lonial, ML Arellano, HJ Khoury, FR Khuri, BH Lee, K Ye, TJ Boggon, S Kang, C He, J Chen	11/13/2012
Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia. Cancer	M Arellano, S Pakkala, A Langston, M Tighiouart, L Pan, Z Chen, LT Heffner, S Lonial, E Winton, HJ Khoury	11/01/2012
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood	DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, V Kukreti, N Bahlis, M Alsina, A Chanan-Khan, F Buadi, FJ Reu, G Somlo, J Zonder, K Song, AK Stewart, E Stadtmauer, L Kunkel, S Wear, AF Wong, RZ Orlowski, S Jagannath	10/04/2012
Sequential or combination therapy for multiple myeloma. Expert review of hematology	A Nooka, S Lonial	10/01/2012
Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. British journal of haematology	D Muringampurath-John, DL Jaye, CR Flowers, D Saxe, Z Chen, MJ Lechowicz, DD Weisenburger, M Bast, ML Arellano, L Bernal-Mizrachi, LT Heffner, M McLemore, JL Kaufman, EF Winton, S Lonial, JO Armitage, HJ Khoury	09/01/2012
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leukemia & lymphoma	JL Wolf, D Siegel, H Goldschmidt, K Hazell, PM Bourquelot, BR Bengoudifa, J Matous, R Vij, M de Magalhaes-Silverman, R Abonour, KC Anderson, S Lonial	09/01/2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. International journal of hematology	AA Chanan-Khan, S Lonial, D Weber, I Borrello, R Foà, A Hellmann, M Dimopoulos, AS Swern, R Knight	08/01/2012
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas. Cancer	R Sinha, JL Kaufman, HJ Khoury, N King, PJ Shenoy, C Lewis, K Bumpers, A Hutchison-Rzepka, M Tighiouart, LT Heffner, MJ Lechowicz, S Lonial, CR Flowers	07/15/2012
The era of combination therapy in myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, JL Kaufman	07/10/2012
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood	R Vij, M Wang, JL Kaufman, S Lonial, AJ Jakubowiak, AK Stewart, V Kukreti, S Jagannath, KT McDonagh, M Alsina, NJ Bahlis, FJ Reu, NY Gabrail, A Belch, JV Matous, P Lee, P Rosen, M Sebag, DH Vesole, LA Kunkel, SM Wear, AF Wong, RZ Orlowski, DS Siegel	06/14/2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	S Lonial, R Vij, JL Harousseau, T Facon, P Moreau, A Mazumder, JL Kaufman, X Leleu, LC Tsao, C Westland, AK Singhal, S Jagannath	06/01/2012
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy	DJ Klionsky, FC Abdalla, H Abeliovich, RT Abraham, A Acevedo-Arozena, K Adeli, L Agholme, M Agnello, P Agostinis, JA Aguirre-Ghiso, HJ Ahn, O Ait-Mohamed, S Ait-Si-Ali, T Akematsu, S Akira, HM Al-Younes, MA Al-Zeer, ML Albert, RL Albin, J Alegre-Abarrategui, MF Aleo, M Alirezaei, A Almasan, M Almonte-Becerril, A Amano, R Amaravadi, S Amarnath, AO Amer, N Andrieu-Abadie, V Anantharam, DK Ann, S Anoopkumar-Dukie, H Aoki, N Apostolova, G Arancia, JP Aris, K Asanuma, NY Asare, H Ashida, V Askanas, DS Askew, P Auberger, M Baba, SK Backues, EH Baehrecke, BA Bahr, XY Bai, Y Bailly, R Baiocchi, G Baldini, W Balduini, A Ballabio, BA Bamber, ET Bampton, G Bánhegyi, CR Bartholomew, DC Bassham, RC Bast, H Batoko, BH Bay, I Beau, DM Béchet, TJ Begley, C Behl, C Behrends, S Bekri, B Bellaire, LJ Bendall, L Benetti, L Berliocchi, H Bernardi, F Bernassola, S Besteiro, I Bhatia-Kissova, X Bi, M Biard-Piechaczyk, JS Blum, LH Boise, P Bonaldo, DL Boone, BC Bornhauser, KR Bortoluci, I Bossis, F Bost, JP Bourquin, P Boya, M Boyer-Guittaut, PV Bozhkov, NR Brady, C Brancolini, A Brech, JE Brenman, A Brennand, EH Bresnick, P Brest, D Bridges, ML Bristol, PS Brookes, EJ Brown, JH Brumell, N Brunetti-Pierri, UT Brunk, DE Bulman, SJ Bultman, G Bultynck, LF Burbulla, W Bursch, JP Butchar, W Buzgariu, SP Bydlowski, K Cadwell, M Cahová, D Cai, J Cai, Q Cai, B Calabretta, J Calvo-Garrido, N Camougrand, M Campanella, J Campos-Salinas, E Candi, L Cao, AB Caplan, SR Carding, SM Cardoso, JS Carew, CR Carlin, V Carmignac, LA Carneiro, S Carra, RA Caruso, G Casari, C Casas, R Castino, E Cebollero, F Cecconi, J Celli, H Chaachouay, HJ Chae, CY Chai, DC Chan, EY Chan, RC Chang, CM Che, CC Chen, GC Chen, GQ Chen, M Chen, Q Chen, SS Chen, W Chen, X Chen, X Chen, X Chen, YG Chen, Y Chen, Y Chen, YJ Chen, Z Chen, A Cheng, CH Cheng, Y Cheng, H Cheong, JH Cheong, S Cherry, R Chess-Williams, ZH Cheung, E Chevet, HL Chiang, R Chiarelli, T Chiba, LS Chin, SH Chiou, FV Chisari, CH Cho, DH Cho, AM Choi, D Choi, KS Choi, ME Choi, S Chouaib, D Choubey, V Choubey, CT Chu, TH Chuang, SH Chueh, T Chun, YJ Chwae, ML Chye, R Ciarcia, MR Ciriolo, MJ Clague, RS Clark, PG Clarke, R Clarke, P Codogno, HA Coller, MI Colombo, S Comincini, M Condello, F Condorelli, MR Cookson, GH Coombs, I Coppens, R Corbalan, P Cossart, P Costelli, S Costes, A Coto-Montes, E Couve, FP Coxon, JM Cregg, JL Crespo, MJ Cronjé, AM Cuervo, JJ Cullen, MJ Czaja, M D'Amelio, A Darfeuille-Michaud, LM Davids, FE Davies, M De Felici, JF de Groot, CA de Haan, L De Martino, A De Milito, V De Tata, J Debnath, A Degterev, B Dehay, LM Delbridge, F Demarchi, YZ Deng, J Dengjel, P Dent, D Denton, V Deretic, SD Desai, RJ Devenish, M Di Gioacchino, G Di Paolo, C Di Pietro, G Díaz-Araya, I Díaz-Laviada, MT Diaz-Meco, J Diaz-Nido, I Dikic, SP Dinesh-Kumar, WX Ding, CW Distelhorst, A Diwan, M Djavaheri-Mergny, S Dokudovskaya, Z Dong, FC Dorsey, V Dosenko, JJ Dowling, S Doxsey, M Dreux, ME Drew, Q Duan, MA Duchosal, K Duff, I Dugail, M Durbeej, M Duszenko, CL Edelstein, AL Edinger, G Egea, L Eichinger, NT Eissa, S Ekmekcioglu, WS El-Deiry, Z Elazar, M Elgendy, LM Ellerby, KE Eng, AM Engelbrecht, S Engelender, J Erenpreisa, R Escalante, A Esclatine, EL Eskelinen, L Espert, V Espina, H Fan, J Fan, QW Fan, Z Fan, S Fang, Y Fang, M Fanto, A Fanzani, T Farkas, JC Farré, M Faure, M Fechheimer, CG Feng, J Feng, Q Feng, Y Feng, L Fésüs, R Feuer, ME Figueiredo-Pereira, GM Fimia, DC Fingar, S Finkbeiner, T Finkel, KD Finley, F Fiorito, EA Fisher, PB Fisher, M Flajolet, ML Florez-McClure, S Florio, EA Fon, F Fornai, F Fortunato, R Fotedar, DH Fowler, HS Fox, R Franco, LB Frankel, M Fransen, JM Fuentes, J Fueyo, J Fujii, K Fujisaki, E Fujita, M Fukuda, RH Furukawa, M Gaestel, P Gailly, M Gajewska, B Galliot, V Galy, S Ganesh, B Ganetzky, IG Ganley, FB Gao, GF Gao, J Gao, L Garcia, G Garcia-Manero, M Garcia-Marcos, M Garmyn, AL Gartel, E Gatti, M Gautel, TR Gawriluk, ME Gegg, J Geng, M Germain, JE Gestwicki, DA Gewirtz, S Ghavami, P Ghosh, AM Giammarioli, AN Giatromanolaki, SB Gibson, RW Gilkerson, ML Ginger, HN Ginsberg, J Golab, MS Goligorsky, P Golstein, C Gomez-Manzano, E Goncu, C Gongora, CD Gonzalez, R Gonzalez, C González-Estévez, RA González-Polo, E Gonzalez-Rey, NV Gorbunov, S Gorski, S Goruppi, RA Gottlieb, D Gozuacik, GE Granato, GD Grant, KN Green, A Gregorc, F Gros, C Grose, TW Grunt, P Gual, JL Guan, KL Guan, SM Guichard, AS Gukovskaya, I Gukovsky, J Gunst, AB Gustafsson, AJ Halayko, AN Hale, SK Halonen, M Hamasaki, F Han, T Han, MK Hancock, M Hansen, H Harada, M Harada, SE Hardt, JW Harper, AL Harris, J Harris, SD Harris, M Hashimoto, JA Haspel, S Hayashi, LA Hazelhurst, C He, YW He, MJ Hébert, KA Heidenreich, MH Helfrich, GV Helgason, EP Henske, B Herman, PK Herman, C Hetz, S Hilfiker, JA Hill, LJ Hocking, P Hofman, TG Hofmann, J Höhfeld, TL Holyoake, MH Hong, DA Hood, GS Hotamisligil, EJ Houwerzijl, M Høyer-Hansen, B Hu, CA Hu, HM Hu, Y Hua, C Huang, J Huang, S Huang, WP Huang, TB Huber, WK Huh, TH Hung, TR Hupp, GM Hur, JB Hurley, SN Hussain, PJ Hussey, JJ Hwang, S Hwang, A Ichihara, S Ilkhanizadeh, K Inoki, T Into, V Iovane, JL Iovanna, NY Ip, Y Isaka, H Ishida, C Isidoro, K Isobe, A Iwasaki, M Izquierdo, Y Izumi, PM Jaakkola, M Jäättelä, GR Jackson, WT Jackson, B Janji, M Jendrach, JH Jeon, EB Jeung, H Jiang, H Jiang, JX Jiang, M Jiang, Q Jiang, X Jiang, X Jiang, A Jiménez, M Jin, S Jin, CO Joe, T Johansen, DE Johnson, GV Johnson, NL Jones, B Joseph, SK Joseph, AM Joubert, G Juhász, L Juillerat-Jeanneret, CH Jung, YK Jung, K Kaarniranta, A Kaasik, T Kabuta, M Kadowaki, K Kagedal, Y Kamada, VO Kaminskyy, HH Kampinga, H Kanamori, C Kang, KB Kang, KI Kang, R Kang, YA Kang, T Kanki, TD Kanneganti, H Kanno, AG Kanthasamy, A Kanthasamy, V Karantza, GP Kaushal, S Kaushik, Y Kawazoe, PY Ke, JH Kehrl, A Kelekar, C Kerkhoff, DH Kessel, H Khalil, JA Kiel, AA Kiger, A Kihara, DR Kim, DH Kim, DH Kim, EK Kim, HR Kim, JS Kim, JH Kim, JC Kim, JK Kim, PK Kim, SW Kim, YS Kim, Y Kim, A Kimchi, AC Kimmelman, JS King, TJ Kinsella, V Kirkin, LA Kirshenbaum, K Kitamoto, K Kitazato, L Klein, WT Klimecki, J Klucken, E Knecht, BC Ko, JC Koch, H Koga, JY Koh, YH Koh, M Koike, M Komatsu, E Kominami, HJ Kong, WJ Kong, VI Korolchuk, Y Kotake, MI Koukourakis, JB Kouri Flores, AL Kovács, C Kraft, D Krainc, H Krämer, C Kretz-Remy, AM Krichevsky, G Kroemer, R Krüger, O Krut, NT Ktistakis, CY Kuan, R Kucharczyk, A Kumar, R Kumar, S Kumar, M Kundu, HJ Kung, T Kurz, HJ Kwon, AR La Spada, F Lafont, T Lamark, J Landry, JD Lane, P Lapaquette, JF Laporte, L László, S Lavandero, JN Lavoie, R Layfield, PA Lazo, W Le, L Le Cam, DJ Ledbetter, AJ Lee, BW Lee, GM Lee, J Lee, JH Lee, M Lee, MS Lee, SH Lee, C Leeuwenburgh, P Legembre, R Legouis, M Lehmann, HY Lei, QY Lei, DA Leib, J Leiro, JJ Lemasters, A Lemoine, MS Lesniak, D Lev, VV Levenson, B Levine, E Levy, F Li, JL Li, L Li, S Li, W Li, XJ Li, YB Li, YP Li, C Liang, Q Liang, YF Liao, PP Liberski, A Lieberman, HJ Lim, KL Lim, K Lim, CF Lin, FC Lin, J Lin, JD Lin, K Lin, WW Lin, WC Lin, YL Lin, R Linden, P Lingor, J Lippincott-Schwartz, MP Lisanti, PB Liton, B Liu, CF Liu, K Liu, L Liu, QA Liu, W Liu, YC Liu, Y Liu, RA Lockshin, CN Lok, S Lonial, B Loos, G Lopez-Berestein, C López-Otín, L Lossi, MT Lotze, P Lőw, B Lu, B Lu, B Lu, Z Lu, F Luciano, NW Lukacs, AH Lund, MA Lynch-Day, Y Ma, F Macian, JP MacKeigan, KF Macleod, F Madeo, L Maiuri, MC Maiuri, D Malagoli, MC Malicdan, W Malorni, N Man, EM Mandelkow, S Manon, I Manov, K Mao, X Mao, Z Mao, P Marambaud, D Marazziti, YL Marcel, K Marchbank, P Marchetti, SJ Marciniak, M Marcondes, M Mardi, G Marfe, G Mariño, M Markaki, MR Marten, SJ Martin, C Martinand-Mari, W Martinet, M Martinez-Vicente, M Masini, P Matarrese, S Matsuo, R Matteoni, A Mayer, NM Mazure, DJ McConkey, MJ McConnell, C McDermott, C McDonald, GM McInerney, SL McKenna, B McLaughlin, PJ McLean, CR McMaster, GA McQuibban, AJ Meijer, MH Meisler, A Meléndez, TJ Melia, G Melino, MA Mena, JA Menendez, RF Menna-Barreto, MB Menon, FM Menzies, CA Mercer, A Merighi, DE Merry, S Meschini, CG Meyer, TF Meyer, CY Miao, JY Miao, PA Michels, C Michiels, D Mijaljica, A Milojkovic, S Minucci, C Miracco, CK Miranti, I Mitroulis, K Miyazawa, N Mizushima, B Mograbi, S Mohseni, X Molero, B Mollereau, F Mollinedo, T Momoi, I Monastyrska, MM Monick, MJ Monteiro, MN Moore, R Mora, K Moreau, PI Moreira, Y Moriyasu, J Moscat, S Mostowy, JC Mottram, T Motyl, CE Moussa, S Müller, S Muller, K Münger, C Münz, LO Murphy, ME Murphy, A Musarò, I Mysorekar, E Nagata, K Nagata, A Nahimana, U Nair, T Nakagawa, K Nakahira, H Nakano, H Nakatogawa, M Nanjundan, NI Naqvi, DP Narendra, M Narita, M Navarro, ST Nawrocki, TY Nazarko, A Nemchenko, MG Netea, TP Neufeld, PA Ney, IP Nezis, HP Nguyen, D Nie, I Nishino, C Nislow, RA Nixon, T Noda, AA Noegel, A Nogalska, S Noguchi, L Notterpek, I Novak, T Nozaki, N Nukina, T Nürnberger, B Nyfeler, K Obara, TD Oberley, S Oddo, M Ogawa, T Ohashi, K Okamoto, NL Oleinick, FJ Oliver, LJ Olsen, S Olsson, O Opota, TF Osborne, GK Ostrander, K Otsu, JH Ou, M Ouimet, M Overholtzer, B Ozpolat, P Paganetti, U Pagnini, N Pallet, GE Palmer, C Palumbo, T Pan, T Panaretakis, UB Pandey, Z Papackova, I Papassideri, I Paris, J Park, OK Park, JB Parys, KR Parzych, S Patschan, C Patterson, S Pattingre, JM Pawelek, J Peng, DH Perlmutter, I Perrotta, G Perry, S Pervaiz, M Peter, GJ Peters, M Petersen, G Petrovski, JM Phang, M Piacentini, P Pierre, V Pierrefite-Carle, G Pierron, R Pinkas-Kramarski, A Piras, N Piri, LC Platanias, S Pöggeler, M Poirot, A Poletti, C Poüs, M Pozuelo-Rubio, M Prætorius-Ibba, A Prasad, M Prescott, M Priault, N Produit-Zengaffinen, A Progulske-Fox, T Proikas-Cezanne, S Przedborski, K Przyklenk, R Puertollano, J Puyal, SB Qian, L Qin, ZH Qin, SE Quaggin, N Raben, H Rabinowich, SW Rabkin, I Rahman, A Rami, G Ramm, G Randall, F Randow, VA Rao, JC Rathmell, B Ravikumar, SK Ray, BH Reed, JC Reed, F Reggiori, A Régnier-Vigouroux, AS Reichert, JJ Reiners, RJ Reiter, J Ren, JL Revuelta, CJ Rhodes, K Ritis, E Rizzo, J Robbins, M Roberge, H Roca, MC Roccheri, S Rocchi, HP Rodemann, S Rodríguez de Córdoba, B Rohrer, IB Roninson, K Rosen, MM Rost-Roszkowska, M Rouis, KM Rouschop, F Rovetta, BP Rubin, DC Rubinsztein, K Ruckdeschel, EB Rucker, A Rudich, E Rudolf, N Ruiz-Opazo, R Russo, TE Rusten, KM Ryan, SW Ryter, DM Sabatini, J Sadoshima, T Saha, T Saitoh, H Sakagami, Y Sakai, GH Salekdeh, P Salomoni, PM Salvaterra, G Salvesen, R Salvioli, AM Sanchez, JA Sánchez-Alcázar, R Sánchez-Prieto, M Sandri, U Sankar, P Sansanwal, L Santambrogio, S Saran, S Sarkar, M Sarwal, C Sasakawa, A Sasnauskiene, M Sass, K Sato, M Sato, AH Schapira, M Scharl, HM Schätzl, W Scheper, S Schiaffino, C Schneider, ME Schneider, R Schneider-Stock, PV Schoenlein, DF Schorderet, C Schüller, GK Schwartz, L Scorrano, L Sealy, PO Seglen, J Segura-Aguilar, I Seiliez, O Seleverstov, C Sell, JB Seo, D Separovic, V Setaluri, T Setoguchi, C Settembre, JJ Shacka, M Shanmugam, IM Shapiro, E Shaulian, RJ Shaw, JH Shelhamer, HM Shen, WC Shen, ZH Sheng, Y Shi, K Shibuya, Y Shidoji, JJ Shieh, CM Shih, Y Shimada, S Shimizu, T Shintani, OS Shirihai, GC Shore, AA Sibirny, SB Sidhu, B Sikorska, EC Silva-Zacarin, A Simmons, AK Simon, HU Simon, C Simone, A Simonsen, DA Sinclair, R Singh, D Sinha, FA Sinicrope, A Sirko, PM Siu, E Sivridis, V Skop, VP Skulachev, RS Slack, SS Smaili, DR Smith, MS Soengas, T Soldati, X Song, AK Sood, TW Soong, F Sotgia, SA Spector, CD Spies, W Springer, SM Srinivasula, L Stefanis, JS Steffan, R Stendel, H Stenmark, A Stephanou, ST Stern, C Sternberg, B Stork, P Strålfors, CS Subauste, X Sui, D Sulzer, J Sun, SY Sun, ZJ Sun, JJ Sung, K Suzuki, T Suzuki, MS Swanson, C Swanton, ST Sweeney, LK Sy, G Szabadkai, I Tabas, H Taegtmeyer, M Tafani, K Takács-Vellai, Y Takano, K Takegawa, G Takemura, F Takeshita, NJ Talbot, KS Tan, K Tanaka, K Tanaka, D Tang, D Tang, I Tanida, BA Tannous, N Tavernarakis, GS Taylor, GA Taylor, JP Taylor, LS Terada, A Terman, G Tettamanti, K Thevissen, CB Thompson, A Thorburn, M Thumm, F Tian, Y Tian, G Tocchini-Valentini, AM Tolkovsky, Y Tomino, L Tönges, SA Tooze, C Tournier, J Tower, R Towns, V Trajkovic, LH Travassos, TF Tsai, MP Tschan, T Tsubata, A Tsung, B Turk, LS Turner, SC Tyagi, Y Uchiyama, T Ueno, M Umekawa, R Umemiya-Shirafuji, VK Unni, MI Vaccaro, EM Valente, G Van den Berghe, IJ van der Klei, W van Doorn, LF van Dyk, M van Egmond, LA van Grunsven, P Vandenabeele, WP Vandenberghe, I Vanhorebeek, EC Vaquero, G Velasco, T Vellai, JM Vicencio, RD Vierstra, M Vila, C Vindis, G Viola, MT Viscomi, OV Voitsekhovskaja, C von Haefen, M Votruba, K Wada, R Wade-Martins, CL Walker, CM Walsh, J Walter, XB Wan, A Wang, C Wang, D Wang, F Wang, F Wang, G Wang, H Wang, HG Wang, HD Wang, J Wang, K Wang, M Wang, RC Wang, X Wang, X Wang, YJ Wang, Y Wang, Z Wang, ZC Wang, Z Wang, DG Wansink, DM Ward, H Watada, SL Waters, P Webster, L Wei, CC Weihl, WA Weiss, SM Welford, LP Wen, CA Whitehouse, JL Whitton, AJ Whitworth, T Wileman, JW Wiley, S Wilkinson, D Willbold, RL Williams, PR Williamson, BG Wouters, C Wu, DC Wu, WK Wu, A Wyttenbach, RJ Xavier, Z Xi, P Xia, G Xiao, Z Xie, Z Xie, DZ Xu, J Xu, L Xu, X Xu, A Yamamoto, A Yamamoto, S Yamashina, M Yamashita, X Yan, M Yanagida, DS Yang, E Yang, JM Yang, SY Yang, W Yang, WY Yang, Z Yang, MC Yao, TP Yao, B Yeganeh, WL Yen, JJ Yin, XM Yin, OJ Yoo, G Yoon, SY Yoon, T Yorimitsu, Y Yoshikawa, T Yoshimori, K Yoshimoto, HJ You, RJ Youle, A Younes, L Yu, L Yu, SW Yu, WH Yu, ZM Yuan, Z Yue, CH Yun, M Yuzaki, O Zabirnyk, E Silva-Zacarin, D Zacks, E Zacksenhaus, N Zaffaroni, Z Zakeri, HJ Zeh, SO Zeitlin, H Zhang, HL Zhang, J Zhang, JP Zhang, L Zhang, L Zhang, MY Zhang, XD Zhang, M Zhao, YF Zhao, Y Zhao, ZJ Zhao, X Zheng, B Zhivotovsky, Q Zhong, CZ Zhou, C Zhu, WG Zhu, XF Zhu, X Zhu, Y Zhu, T Zoladek, WX Zong, A Zorzano, J Zschocke, B Zuckerbraun	04/01/2012
Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma. Leukemia & lymphoma	D Muringampurath-John, CR Flowers, M Toscano, C Zhengjia, JL Kaufman, M Arellano, L Bernal-Mizrachi, LT Heffner, MJ Lechowicz, M McLemore, E Winton, DL Jaye, S Lonial, HJ Khoury	04/01/2012
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Molecular cell	T Hitosugi, J Fan, TW Chung, K Lythgoe, X Wang, J Xie, Q Ge, TL Gu, RD Polakiewicz, JL Roesel, GZ Chen, TJ Boggon, S Lonial, H Fu, FR Khuri, S Kang, J Chen	12/23/2011
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood	P Neri, L Ren, K Gratton, E Stebner, J Johnson, A Klimowicz, P Duggan, P Tassone, A Mansoor, DA Stewart, S Lonial, LH Boise, NJ Bahlis	12/08/2011
Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells. Molecular and cellular biology	J Fan, T Hitosugi, TW Chung, J Xie, Q Ge, TL Gu, RD Polakiewicz, GZ Chen, TJ Boggon, S Lonial, FR Khuri, S Kang, J Chen	12/01/2011
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Molecular cancer therapeutics	L Zhao, P Yue, S Lonial, FR Khuri, SY Sun	12/01/2011
Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma. Oncology (Williston Park, N.Y.)	S Lonial, LH Boise	11/15/2011
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	PG Richardson, J Wolf, A Jakubowiak, J Zonder, S Lonial, D Irwin, J Densmore, A Krishnan, N Raje, M Bar, T Martin, R Schlossman, IM Ghobrial, N Munshi, J Laubach, J Allerton, T Hideshima, K Colson, E Poradosu, L Gardner, P Sportelli, KC Anderson	11/10/2011
Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clinical lymphoma, myeloma & leukemia	A Nooka, PJ Shenoy, R Sinha, S Lonial, CR Flowers	10/01/2011
Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion	J Li, E Hamilton, L Vaughn, M Graiser, H Renfroe, MJ Lechowicz, A Langston, JM Prichard, D Anderson, C Gleason, S Lonial, CR Flowers, JL Kaufman, EK Waller	10/01/2011
Monoclonal antibodies in the treatment of multiple myeloma. British journal of haematology	PG Richardson, S Lonial, AJ Jakubowiak, JL Harousseau, KC Anderson	09/01/2011
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood	AA Morales, M Kurtoglu, SM Matulis, J Liu, D Siefker, DM Gutman, JL Kaufman, KP Lee, S Lonial, LH Boise	08/04/2011
A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation. Transfusion	H Renfroe, M Arnold, L Vaughn, RD Harvey, E Hamilton, S Lonial, HJ Khoury, JL Kaufman, MJ Lechowicz, CR Flowers, EK Waller	08/01/2011
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. British journal of haematology	PG Richardson, AA Chanan-Khan, S Lonial, AY Krishnan, MP Carroll, M Alsina, M Albitar, D Berman, M Messina, KC Anderson	06/01/2011
Is subcutaneous bortezomib ready for prime time? Current hematologic malignancy reports	S Lonial	06/01/2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood	SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, R Kyle, J Blade, P Richardson, R Orlowski, D Siegel, S Jagannath, T Facon, H Avet-Loiseau, S Lonial, A Palumbo, J Zonder, H Ludwig, D Vesole, O Sezer, NC Munshi, J San Miguel	05/05/2011
Farnesyl transferase inhibitors, autophagy, and proteasome inhibition: synergy for all the right reasons. Autophagy	S Lonial, LH Boise	04/01/2011
Treatment options for relapsed and refractory multiple myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research	S Lonial, CS Mitsiades, PG Richardson	03/15/2011
Putting the E (evidence) in a new Era for myeloma. Leukemia & lymphoma	JL Kaufman, S Lonial	03/01/2011
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. British journal of haematology	PG Richardson, CS Mitsiades, JP Laubach, S Lonial, AA Chanan-Khan, KC Anderson	02/01/2011
Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia	CR Giver, DL Jaye, EK Waller, JL Kaufman, S Lonial	02/01/2011
Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer chemotherapy and pharmacology	DE Reece, D Sullivan, S Lonial, AF Mohrbacher, G Chatta, C Shustik, H Burris, K Venkatakrishnan, R Neuwirth, WJ Riordan, M Karol, LL von Moltke, M Acharya, P Zannikos, A Keith Stewart	01/01/2011
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood	E David, JL Kaufman, CR Flowers, K Schafer-Hales, C Torre, J Chen, AI Marcus, SY Sun, LH Boise, S Lonial	12/09/2010
Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease. Transfusion	M Akhtari, CR Giver, Z Ali, CR Flowers, CL Gleason, CD Hillyer, J Kaufman, HJ Khoury, AA Langston, MJ Lechowicz, S Lonial, HM Renfroe, JD Roback, M Tighiouart, L Vaughn, EK Waller	11/01/2010
A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clinical cancer research : an official journal of the American Association for Cancer Research	S Lonial, J Kaufman, M Tighiouart, A Nooka, AA Langston, LT Heffner, C Torre, S McMillan, H Renfroe, RD Harvey, MJ Lechowicz, HJ Khoury, CR Flowers, EK Waller	10/15/2010
Melphalan or no melphalan: that is the question. Oncology (Williston Park, N.Y.)	J Kaufman, S Lonial	10/01/2010
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leukemia research	S Jagannath, MA Dimopoulos, S Lonial	09/01/2010
The White House crusade against ... MGUS? Blood	S Lonial	08/19/2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood	PG Richardson, E Weller, S Lonial, AJ Jakubowiak, S Jagannath, NS Raje, DE Avigan, W Xie, IM Ghobrial, RL Schlossman, A Mazumder, NC Munshi, DH Vesole, R Joyce, JL Kaufman, D Doss, DL Warren, LE Lunde, S Kaster, C Delaney, T Hideshima, CS Mitsiades, R Knight, DL Esseltine, KC Anderson	08/05/2010
Monoclonal gammopathy of undetermined significance: a consensus statement. British journal of haematology	JR Berenson, KC Anderson, RA Audell, RV Boccia, M Coleman, MA Dimopoulos, MT Drake, R Fonseca, JL Harousseau, D Joshua, S Lonial, R Niesvizky, A Palumbo, GD Roodman, JF San-Miguel, S Singhal, DM Weber, M Zangari, E Wirtschafter, O Yellin, RA Kyle	07/01/2010
Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Cancer	JL Kaufman, A Nooka, M Vrana, C Gleason, LT Heffner, S Lonial	07/01/2010
Improving induction therapy in multiple myeloma. Current hematologic malignancy reports	A Nooka, C Gleason, S Lonial	07/01/2010
Future directions in immunomodulatory therapy. Medical oncology (Northwood, London, England)	S Lonial	06/01/2010
Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. The Journal of biological chemistry	C Li, S Chen, P Yue, X Deng, S Lonial, FR Khuri, SY Sun	05/21/2010
Presentation and risk stratification--improving prognosis for patients with multiple myeloma. Cancer treatment reviews	S Lonial	05/01/2010
Frontline regimens for multiple myeloma patients. Clinical advances in hematology & oncology : H&O	S Lonial	05/01/2010
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clinic proceedings	R Fonseca, P Richardson, S Giralt, S Lonial, SV Rajkumar, AK Stewart, W Bensinger, G Somlo, R Vescio, J Mikhael, C Reeder, R Tiedemann, G Tricot, R Rifkin, J Shaughnessy, N Munshi, N Raje, I Ghobrial, J Laubach, R Schlossman, S Treon, A Mahindra, D Avigan, J Rosenblatt, S Jagannath, R Niesvizky, H Landau, S Chen-Kiang, DS Siegel, T Zimmerman, J Mehta, D Vesole, S Rosen, C Hofmeister, M Lacy, A Dispenzieri, I Borrello, SR Hayman, S Kumar, F Buadi, D Dingli, S Russell, MA Melissa Alsina, H Fernandez, V Roy, D Pereira, E Stadtmauer, R Vij, A Jakubowiak, S Lentzsch, K Song, S Trudel, C Chen, D Reece, D Stewart, S Singhal, R Comenzo, MA Gertz, PR Greipp, B Durie, B Barlogie, K Anderson, W Dalton, M Coleman, S Novis, RA Kyle	02/01/2010
Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. Hematology. American Society of Hematology. Education Program	N Shah, S Lonial	01/01/2010
Relapsed multiple myeloma. Hematology. American Society of Hematology. Education Program	S Lonial	01/01/2010
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer research	L Fu, YA Kim, X Wang, X Wu, P Yue, S Lonial, FR Khuri, SY Sun	12/01/2009
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Science signaling	T Hitosugi, S Kang, MG Vander Heiden, TW Chung, S Elf, K Lythgoe, S Dong, S Lonial, X Wang, GZ Chen, J Xie, TL Gu, RD Polakiewicz, JL Roesel, TJ Boggon, FR Khuri, DG Gilliland, LC Cantley, J Kaufman, J Chen	11/17/2009
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'. Leukemia	RD Harvey, J Nettles, B Wang, SY Sun, S Lonial	11/01/2009
Supportive therapies in multiple myeloma. Journal of the National Comprehensive Cancer Network : JNCCN	C Gleason, A Nooka, S Lonial	10/01/2009
Risky business in myeloma. Blood	S Lonial	07/16/2009
Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease. American heart journal	V Subramaniyam, EK Waller, JR Murrow, A Manatunga, S Lonial, K Kasirajan, D Sutcliffe, W Harris, WR Taylor, RW Alexander, AA Quyyumi	07/01/2009
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. British journal of haematology	S Lonial, J Cavenagh	06/01/2009
Treatment of multiple myeloma: whence truth over belief? Oncology (Williston Park, N.Y.)	J Kaufman, S Lonial	04/30/2009
Treatment of relapsed and refractory myeloma. Current hematologic malignancy reports	J Kaufman, C Gleason, S Lonial	04/01/2009
The importance of complete response in outcomes in myeloma. Cancer journal (Sudbury, Mass.)	A Nooka, J Kaufman, S Lonial	01/01/2009
Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma. Bone marrow transplantation	S Murali, E Winton, EK Waller, LT Heffner, S Lonial, C Flowers, J Kaufman, M Arellano, MJ Lechowicz, KP Mann, HJ Khoury, AA Langston	10/01/2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. British journal of haematology	S Lonial, PG Richardson, J San Miguel, P Sonneveld, MW Schuster, J Bladé, J Cavenagh, SV Rajkumar, AJ Jakubowiak, DL Esseltine, KC Anderson, JL Harousseau	10/01/2008
Regulation of alloimmune responses by dendritic cell subsets. Experimental hematology	S Lonial, C Torre, E David, W Harris, M Arellano, EK Waller	10/01/2008
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors. Clinical cancer research : an official journal of the American Association for Cancer Research	E David, R Sinha, J Chen, SY Sun, JL Kaufman, S Lonial	08/15/2008
Practical considerations for multiple myeloma: an overview of recent data and current options. Clinical lymphoma & myeloma	S Lonial	08/01/2008
Review of peripheral neuropathy in plasma cell disorders. Hematological oncology	J Silberman, S Lonial	06/01/2008
Eliminating the complete response penalty from myeloma response assessment. Blood	S Lonial, MA Gertz	03/15/2008
Clinical uses of GM-CSF, a critical appraisal and update. Biologics : targets & therapy	M Arellano, S Lonial	03/01/2008
Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia	S Dong, S Kang, S Lonial, HJ Khoury, J Viallet, J Chen	03/01/2008
Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. The Journal of biological chemistry	S Kang, S Dong, A Guo, H Ruan, S Lonial, HJ Khoury, TL Gu, J Chen	02/22/2008
Multiple myeloma presenting with advanced renal failure: a case report and new treatment options. Clinical lymphoma & myeloma	SP Gladney, S Lonial, JL Kaufman	02/01/2008
Multiple myeloma: novel approaches for relapsed disease. Clinical lymphoma & myeloma	S Lonial	12/01/2007
PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future oncology (London, England)	RD Harvey, S Lonial	12/01/2007
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. The New England journal of medicine	DM Weber, C Chen, R Niesvizky, M Wang, A Belch, EA Stadtmauer, D Siegel, I Borrello, SV Rajkumar, AA Chanan-Khan, S Lonial, Z Yu, J Patin, M Olesnyckyj, JB Zeldis, RD Knight	11/22/2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood	PG Richardson, P Sonneveld, M Schuster, D Irwin, E Stadtmauer, T Facon, JL Harousseau, D Ben-Yehuda, S Lonial, H Goldschmidt, D Reece, JS Miguel, J Bladé, M Boccadoro, J Cavenagh, M Alsina, SV Rajkumar, M Lacy, A Jakubowiak, W Dalton, A Boral, DL Esseltine, D Schenkein, KC Anderson	11/15/2007
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clinical advances in hematology & oncology : H&O	EA Stadtmauer, S Lonial, DH Vesole, R Abonour, M Alsina, A Badros, R Comenzo, B Durie, S Giralt, M Hussein, A Jakubowiak, J Mehta, R Niesvizky, R Orlowski, D Siegel, S Singhal, R Vescio, M Wang, M Zangari, NC Munshi	10/01/2007
FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer cell	S Kang, S Dong, TL Gu, A Guo, MS Cohen, S Lonial, HJ Khoury, D Fabbro, DG Gilliland, PL Bergsagel, J Taunton, RD Polakiewicz, J Chen	09/01/2007
Complete remission of multiple myeloma. Clinical advances in hematology & oncology : H&O	S Lonial	09/01/2007
Maintenance therapy in lymphoma. Clinical lymphoma & myeloma	R Mihelic, J Kaufman, S Lonial, C Flowers	09/01/2007
14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood	S Dong, S Kang, TL Gu, S Kardar, H Fu, S Lonial, HJ Khoury, F Khuri, J Chen	07/01/2007
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway. Molecular cancer therapeutics	HA Elrod, YD Lin, P Yue, X Wang, S Lonial, FR Khuri, SY Sun	07/01/2007
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. British journal of haematology	PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, T Facon, JL Harousseau, D Ben-Yehuda, S Lonial, JF San Miguel, JD Cavenagh, KC Anderson	06/01/2007
The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. Cancer research	Y Qiu, X Liu, W Zou, P Yue, S Lonial, FR Khuri, SY Sun	05/15/2007
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer research	X Liu, P Yue, S Chen, L Hu, S Lonial, FR Khuri, SY Sun	05/15/2007
Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion	ML Hicks, S Lonial, A Langston, C Flowers, JD Roback, KJ Smith, S Mossavi Sai, D Teagarden, ES Hamilton, EK Waller, J Kaufman	04/01/2007
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood	AA Chanan-Khan, JL Kaufman, J Mehta, PG Richardson, KC Miller, S Lonial, NC Munshi, R Schlossman, J Tariman, S Singhal	03/15/2007
Designing risk-adapted therapy for multiple myeloma: the Mayo perspective. Mayo Clinic proceedings	S Lonial	03/01/2007
Racial differences in the incidence and outcomes for patients with hematological malignancies. Current problems in cancer	CR Flowers, R Glover, S Lonial, OW Brawley	01/01/2007
Management of toxicities associated with bortezomib. Oncology (Williston Park, N.Y.)	S Lonial	11/01/2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	RI Fisher, SH Bernstein, BS Kahl, B Djulbegovic, MJ Robertson, S de Vos, E Epner, A Krishnan, JP Leonard, S Lonial, EA Stadtmauer, OA O'Connor, H Shi, AL Boral, A Goy	10/20/2006
Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Leukemia & lymphoma	S Lonial, M Arellano, D Hutcherson, A Langston, C Flowers, LT Heffner, E Winton, M Jo Lechowicz, EK Waller	10/01/2006
Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma. Supportive cancer therapy	GK Reddy, TI Mughal, S Lonial	10/01/2006
Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer	BT Brinker, EK Waller, T Leong, LT Heffner, I Redei, AA Langston, S Lonial	05/15/2006
Novel treatment approaches for patients with relapsed and refractory multiple myeloma. Current treatment options in oncology	R Sinha, S Lonial	05/01/2006
Proteasome inhibition: novel therapy for multiple myeloma. Onkologie	JL Kaufman, S Lonial	04/01/2006
Novel treatment approaches for patients with multiple myeloma. Clinical lymphoma & myeloma	R Sinha, JL Kaufman, S Lonial	01/01/2006
A practical update on the use of bortezomib in the management of multiple myeloma. The oncologist	J San Miguel, J Bladé, M Boccadoro, J Cavenagh, A Glasmacher, S Jagannath, S Lonial, RZ Orlowski, P Sonneveld, H Ludwig	01/01/2006
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood	E David, SY Sun, EK Waller, J Chen, FR Khuri, S Lonial	12/15/2005
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood	S Lonial, EK Waller, PG Richardson, S Jagannath, RZ Orlowski, CR Giver, DL Jaye, D Francis, S Giusti, C Torre, B Barlogie, JR Berenson, S Singhal, DP Schenkein, DL Esseltine, J Anderson, H Xiao, LT Heffner, KC Anderson	12/01/2005
Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004. Expert opinion on investigational drugs	M Haas, S Lonial	09/01/2005
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. The New England journal of medicine	PG Richardson, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, T Facon, JL Harousseau, D Ben-Yehuda, S Lonial, H Goldschmidt, D Reece, JF San-Miguel, J Bladé, M Boccadoro, J Cavenagh, WS Dalton, AL Boral, DL Esseltine, JB Porter, D Schenkein, KC Anderson	06/16/2005
Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity. Expert opinion on biological therapy	JJ Everly, S Lonial	03/01/2005
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	S Lonial, M Hicks, H Rosenthal, A Langston, I Redei, C Torre, M Duenzl, B Feinstein, J Cherry, EK Waller	12/01/2004
Multiple myeloma: the role of transplant and novel treatment strategies. Seminars in oncology	J Kaufman, S Lonial	04/01/2004
Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. Blood cells, molecules & diseases	EK Waller, CR Giver, H Rosenthal, J Somani, AA Langston, S Lonial, JD Roback, JM Li, MS Hossain, I Redei	01/01/2004
Reconstructing immunity after allogeneic transplantation. Immunologic research	CR Giver, JM Li, MS Hossain, S Lonial, EK Waller	01/01/2004
Immunomodulation: the role of hematopoietic cytokines. Supportive cancer therapy	S Lonial	01/01/2004
Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	CR Giver, RO Montes, S Mittelstaedt, JM Li, DL Jaye, S Lonial, MW Boyer, EK Waller	10/01/2003
Hematopoietic cytokines: when treating the symptoms does not treat the disease. Supportive cancer therapy	S Lonial	10/01/2003
Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation	EK Waller, AA Langston, S Lonial, J Cherry, J Somani, AJ Allen, H Rosenthal, I Redei	07/01/2003
Signal transduction and myeloma: new targets, new hope. Cancer biology & therapy	S Lonial, EK Waller, JW Simons, LT Heffner	01/01/2003
Breakthroughs in the management of multiple myeloma. Drugs	LT Heffner, S Lonial	01/01/2003
A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses. Vaccine	J Somani, S Lonial, H Rosenthal, S Resnick, I Kakhniashvili, EK Waller	12/13/2002
Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood	AA Langston, I Redei, AM Caliendo, J Somani, D Hutcherson, S Lonial, S Bucur, J Cherry, A Allen, EK Waller	02/01/2002
DC2 effect on survival following allogeneic bone marrow transplantation. Oncology (Williston Park, N.Y.)	EK Waller, H Rosenthal, L Sagar	01/01/2002

Awards

Giants of Cancer Care, Myeloma Award Category, OncLive, 2020
MilliPub Club Award, Emory University School of Medicine, 2015, 2020, 2022
Lifetime Achievement Award for Outstanding Contributions to Hematology-Oncology, Indo-American Cancer Association, 2017
Celgene 'Young Investigator' Award
MMRF 'Top 15 Innovator' Award
MMRC 'Center of the Year' award
Multiple Myeloma Research Foundation
Henry B. Macintosh Award, 1996
Houston Society of Internal Medicine, Best Resident in Internal Medicine, 1995

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	07/05/2024	Dr. Lonial is great and caring
One star One star One star One star One star	06/28/2024	There is absolutely no one better than Dr Lonial ANYWHERE IN THE WORLD for his kindness, concern, care, knowledge and expertise. I have been so very blessed by being under his careful watch for over 14 years now. I would not go anywhere else for my care!
One star One star One star One star One star	06/06/2024	Always pleasant.. Explains procedures in a way that they are understood. Answers my questions. Always satisfied.
One star One star One star One star One star	05/30/2024	Dr Lonial s the best. The whole process from registering to getting an appointment, the preliminary instructions, the sign in process, the appointment itself, and the discharge instructions was superior. I didn't know what to expect and I was surprised at the level of excellence that Dr Lonials team expresses. Dr spent a good 45 or so minutes with me and my wife to explain my condition thoroughly with terms that we could understand and outlined a plan of care for me that made good sense. Really impressed with Dr Lonial and the team at Emory Winship.
One star One star One star One star One star	05/12/2024	Dr. Lonial is a wonderful doctor.
One star One star One star One star One star	05/01/2024	Conversation covered lab work with detail so I could make a decision about treatment. Provided options. Answered questions.. When decision was made the process began immediately with upmost expediency. So very professional!
One star One star One star One star One star	05/01/2024	Dr Lonial and his staff treat you like family!! I really enjoy learning about my condition and how they can help me feel safe!! They are the best
One star One star One star One star One star	04/14/2024	Conversations always instructive and beneficial.
One star One star One star One star One star	04/11/2024	Dr. Lonial is the best. He is why I'm at Emory.
One star One star One star One star One star	04/03/2024	Was so pleased they wanted to spend the time explaining everything
One star One star One star One star One star	02/21/2024	Dr. Lonial is super impressive. An amazing person.
One star One star One star One star One star	02/16/2024	I love Dr Lonial he is so smart and easy to talk to.
One star One star One star One star One star	02/09/2024	I am very comfortable and pleased with the excellent care that I am getting.
One star One star One star One star One star	01/31/2024	Dr Lonial is outstanding ,brilliant ,compassionate ,Explains everything ,has kept me alive with multiple myeloma for 11 years and probably will for another 10 at least.My family and I are so grateful.
One star One star One star One star One star	01/17/2024	I share my wonderful experience often
One star One star One star One star One star	01/10/2024	Good
One star One star One star One star One star	01/10/2024	Dr Lonial is a great physician, listener and he always takes great care to involve the patient! He always asks what questions and concerns I have and takes the time to answer each one fully!Thank you for caring about me and wanting me to be as healthy as possible.
One star One star One star One star One star	12/15/2023	Dr. Lonial, with a very busy schedule, allocated the time needed for our discussion.
One star One star One star One star One star	11/11/2023	Dr Lonial was very good about answering my question
One star One star One star One star One star	11/02/2023	It is a pleasure to be cared for by Dr. Lonial, a top provider in his field and still a great communicator.
One star One star One star One star One star	10/25/2023	I have been blessed to have Dr. Sagar Lonial for my multiple myeloma oncologist specialist . He shows compassion , care, and understanding in every area of my cancer journey !! I am eight years in remission from my stem cell transplant multiple myeloma diagnosis !! He has been the best doctor in every area of my care !! I recommend Dr. Lonial and Emory every time I get the opportunity to do so !!!
One star One star One star One star One star	10/11/2023	There is NO better Oncologist than Dr. Lonial!He answers all my questions and is always concerned about anything I have on my mind. I appreciate him so much!
One star One star One star One star One star	10/06/2023	Dr Lonial is outstanding in every way!
One star One star One star One star One star	09/20/2023	Dr. Lonial is the best - he is knowledgeable, and listens carefully, and is very caring.
One star One star One star One star One star	09/13/2023	Very good
One star One star One star One star One star	09/06/2023	Amazing experience. Dr. Lonial was incredibly patient, thorough, knowledge and helpful.
One star One star One star One star One star	08/28/2023	Very good experience
One star One star One star One star One star	08/25/2023	Dr. Loniel is the best.
One star One star One star One star One star	08/16/2023	This was a serous visit, and Dr. Lonial was very thorough in describing future treatment options. He even sent a pharmacist to clarify the differences in possible future care plans
One star One star One star One star One star	07/30/2023	Dr Lonial communication skills gets better over time. Would recommend him to all
One star One star One star One star One star	07/12/2023	Dr Sagar Longial is my doctor. He is excellent.
One star One star One star One star One star	06/08/2023	Dr. Lonial is always very kind, professional and thorough during our visits.
One star One star One star One star One star	04/26/2023	Love Dr Lonial and all of the team! They have cared for me and answered any and all questions I've had! Best care I've ever received!
One star One star One star One star One star	03/22/2023	Dr Lonial is just the best! I have a very trusting relationship with him and have great confidence in his expertise. I feel really blessed to have him as my physician.
One star One star One star One star One star	02/22/2023	Discussions are always pertinent to my particular situation. Reasonable assessments are always welcomed. Patient thorough ..
One star One star One star One star One star	02/01/2023	I have always been able to recommend Emory and feel good to know that they will receive the best of care.
One star One star One star One star One star	01/06/2023	Dr Lonial answered several questions that I had as well as meticulously explaining the results of my lab work.
One star One star One star One star One star	12/28/2022	Dr lonial gave me great news about my latest test and said to keep doing what I'm doing. Come back next year then he set up a request for next year's appointments
One star One star One star One star One star	12/02/2022	Everything was explained to me about my care.
One star One star One star One star One star	11/24/2022	Dr. Lonial always listens very closely and addresses all questions and concerns thoroughly. I trust him impeccably.
One star One star One star One star Empty star	11/06/2022	This is the best hospital around
One star One star One star One star One star	10/26/2022	Dr. Lonial is always very attentive and encouraging of any questions I may have. His explanations are very informative, and his "bedside" manner is excellent. I feel very fortunate to have him in charge of my case.
One star One star One star One star One star	09/22/2022	Dr. Lonial is an excellent communicator.
One star One star One star One star One star	08/27/2022	Dr. Lonial is an amazing Physician - he is very thorough and has a wonderful bedside manner!
One star One star One star One star One star	08/24/2022	Dr. Lonial is the most professional yet friendly and compassionate provider I have ever had. I admire him and trust him impeccably.
One star One star One star One star One star	07/31/2022	I thought those particular caregivers were excellent.
One star One star One star One star One star	07/29/2022	Dr. Lonial is the best!